

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Impacts of chronic kidney disease and other major non-communicable chronic diseases in China: a national study of 19.5 million hospitalizations

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-051888
Article Type:	Original research
Date Submitted by the Author:	31-Mar-2021
Complete List of Authors:	Yang, Chao; Peking University First Hospital, Long, Jianyan; First Affiliated Hospital of Sun Yat-Sen University, Clinical Trial Unit Shi, Ying; China Standard Medical Information Research Center Zhou, Zhiye; China Standard Medical Information Research Center Wang, Jinwei; Peking University First Hospital Zhao, Minhui; Peking University Institute of Nephrology, Renal Division Wang, Haibo; First Affiliated Hospital of Sun Yat-Sen University; National Institute of Health Data Science at Peking University Zhang, Luxia; Peking University First Hospital; National Institute of Health Data Science at Peking University Coresh, J; Johns Hopkins University Bloomberg School of Public Health, Department of Epidemiology
Keywords:	Public health < INFECTIOUS DISEASES, Epidemiology < TROPICAL MEDICINE, Chronic renal failure < NEPHROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Impacts of chronic kidney disease and other major non-communicable**
4 **chronic diseases in China: a national study of 19.5 million**
5
6 **hospitalizations**
7
8
9

10
11 Running head: CKD and NCDs in China
12
13

14
15
16 Chao Yang, MS^{1,2}; Jianyan Long, MSc³; Ying Shi, BMS⁴; Zhiye Zhou, MSc⁴; Jinwei
17
18 Wang, PhD^{1,2}; Ming-Hui Zhao, MD^{1,2,5}; Haibo Wang, MBBS, MSc, MPH^{3,6,*}; Luxia
19
20 Zhang, MD, MPH^{1,6,7,*}; Josef Coresh, MD, PhD⁸
21
22

23
24
25 ¹*Renal Division, Department of Medicine, Peking University First Hospital, Peking*
26
27 *University Institute of Nephrology, Beijing, China*
28

29
30 ²*Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases,*
31
32 *Chinese Academy of Medical Sciences, Beijing, China*
33

34
35 ³*Clinical Trial Unit, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,*
36
37 *Guangdong, China*
38

39
40 ⁴*China Standard Medical Information Research Center, Shenzhen, Guangdong, China*

41
42 ⁵*Peking-Tsinghua Center for Life Sciences, Beijing, China*

43
44 ⁶*National Institute of Health Data Science at Peking University, Beijing, China*

45
46 ⁷*Advanced Institute of Information Technology, Peking University, Hangzhou, Zhejiang,*
47
48 *China*
49

50
51 ⁸*Department of Epidemiology, Johns Hopkins University Bloomberg School of Public*
52
53 *Health, Baltimore, MD, USA*
54

1
2
3 ***Corresponding authors:** Luxia Zhang, MD, MPH, Renal Division, Department of
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Medicine, Peking University First Hospital, Peking University Institute of Nephrology,
No. 8, Xishiku Street, Xicheng District, Beijing 100034, China. Phone: +86-10-8357-
5817, Fax: +86-10-6655-1055, E-mail: zhanglx@bjmu.edu.cn; Haibo Wang, MBBS,
MSc, MPH, Clinical Trial Unit, First Affiliated Hospital of Sun Yat-Sen University,
Guangzhou 510080, China; Phone: +86-755-3331-9080, Fax: +86-755-3331-9061, E-
mail: haibo@mail.harvard.edu.

Abstract

Objective: To evaluate the impacts of chronic kidney disease (CKD) and other major non-communicable chronic diseases (NCDs) on healthcare system in China.

Design: Cross-sectional study.

Setting: A national in-patient database in tertiary hospitals in China.

Participants: 19.5 million hospitalizations of adult patients from July, 2013 to June, 2014. CKD and other major NCDs, including coronary heart disease (CHD), stroke, hypertension, diabetes, chronic obstructive pulmonary diseases (COPD), and cancer were extracted from the unified discharge summary form.

Outcome measures: Costs, length of hospital stay, and in-hospital mortality.

Results: The percentages with CKD, CHD, stroke, hypertension, diabetes, COPD, and cancer were 4.5%, 9.2%, 8.2%, 18.8%, 7.9%, 2.3%, and 19.4%, respectively. For each major NCD, the additional presence of CKD was independently associated with longer hospital stay, with increased percentages ranging from 7.69% (95% confidence interval [CI] 7.11%~8.28%, for stroke) to 21.60% (95% CI 21.09%~22.10%, for CHD). The hospital mortality of other NCDs was also higher in the presence of CKD, with fully adjusted relative risk from 1.91 (95% CI 1.82~1.99, for stroke) to 2.65 (95% CI 2.55~2.75, for cancer). Compared with other NCDs, CKD was associated with the longest hospital stay (22.1% increase), and resulted in the second highest in-hospital mortality, only lower than that of cancer (relative risk of 2.23 vs. 2.87).

Conclusions: The presence of diagnosed CKD alongside each major NCD was associated with an extra burden on healthcare system. The impacts of CKD on healthcare recourse utilization and prognosis were comparable to other major NCDs, which

1
2
3 highlights the importance of CKD as a major public health burden.
4
5
6

7
8 **Keywords**
9

10 Chronic kidney disease; Disease burden; Health care costs; Length of stay; Mortality;
11

12 Non-communicable chronic disease
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

- The first national study that places the CKD burden on hospital stay and mortality in the full context of all major NCDs.
- With large sample size and wide geographical coverage.
- Only tertiary hospitals were included, which might lead to population selection bias.
- Diagnosis of major NCDs was based on the ICD-10 coding with low sensitivity.
- Data of eGFR or proteinuria and information on medications were not available.

Background

The spread of non-communicable diseases (NCDs) presents a global crisis, accounting for 68% of the world's deaths.¹ More importantly, more than 75% of NCDs-related deaths occurred in low- and middle-income countries, exerting a significant influence on healthcare costs.² Hence, the priority actions for the NCDs crisis, mainly heart disease, stroke, cancer, diabetes, and chronic respiratory diseases, were released in 2011.¹ The world leaders also committed to reduce premature deaths from NCDs by one-third by 2030.² Additionally, prevention and control of NCDs are important during this pandemic because NCDs and coronavirus disease 2019 (COVID-19) are closely connected.^{3 4} They share a common set of underlying risk factors and patients with NCDs are more vulnerable to severe COVID-19 and death.⁴

In the past decade, chronic kidney disease (CKD) has been recognized as a major public health issue worldwide, with the estimated prevalence of more than 10%.^{5 6} The burden of kidney diseases goes beyond its impact on the demand of kidney replacement therapy. CKD is a key determinant of the poor health outcomes of major NCDs and a risk multiplier in patients with cardiovascular disease (CVD), diabetes, and hypertension.⁷ Due to the fact that the kidney is usually a target organ of systemic vascular, hemodynamic, metabolic, and inflammatory disorders, the pandemic of NCDs also leads to a persistently increasing morbidity of CKD.⁸ Accumulating evidence based on individual disease revealed that major NCDs including heart disease and stroke had a worse prognosis in the presence of CKD.⁹⁻¹¹ Despite the underlying mechanisms not being fully understood, they might include: 1) CKD as a cause for adverse outcomes, 2) CKD as a marker of systematic disorders, and 3) therapeutic nihilism due to the presence

1
2
3 of CKD.⁶
4

5 While being realized as a global health issue, to the best of our knowledge, there is
6 neither a large-scale study quantitatively evaluating the burden of CKD on all major
7 NCDs, nor a study comparing the burden of CKD with other NCDs. In China, the world's
8 most populous country, CKD is prevalent and associated with more severe comorbidities
9 and higher medical expenditures.^{12 13} However, evidence for the impacts of CKD and
10 other major NCDs on the health care system at a national level is limited, which impedes
11 the development of effective preventive strategies. Hence, we initiated this observational
12 study, to comprehensively and quantitatively evaluate the impact of CKD on resource
13 utilization and prognosis of other NCDs, as well as to compare the burden of kidney
14 diseases on healthcare system with other NCDs among hospitalized patients in China.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Methods**

31 *Study population*

32
33 The Hospital Quality Monitoring System (HQMS) is a mandatory patient-level national
34 database for hospital accreditation under the authority of the National Health
35 Commission of the People's Republic of China. Details of HQMS were described
36 elsewhere.^{14 15} In brief, all tertiary hospitals in China have been requested to submit
37 electronic in-patient discharge records to HQMS on a daily basis. Different from those in
38 the Western medical system, tertiary hospitals in China also provide primary, secondary,
39 and tertiary care and have exposure to nationwide patient population. Patient-level data
40 were collected from uniform front pages of hospitalization medical records. Altogether
41 353 variables including demographic characteristics, clinical diagnoses, procedures,
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 pathology diagnoses, and expenditure breakdowns were collected. All personal
4
5 information has already been de-identified to protect patient privacy. The diagnoses were
6
7 coded based on the International Classification of Diseases-10 (ICD-10) coding system
8
9
10 by certified professional medical coders at every hospital. As the part of stringent
11
12 standard practice in China, the front page has the legal validity and must be filed by the
13
14 care given doctors who have the most accurate and comprehensive understanding of the
15
16 patient's medical condition.
17

18
19 A total of 19,518,990 records of adult in-patients admitted from 1 July 2013 to 30
20
21 June 2014 in 29 provinces (excluding Hong Kong, Macao, Taiwan, Tibet, and Ningxia)
22
23 were included in this cross-sectional study, with certain patients having more than one
24
25 hospitalization. During this period, 715 tertiary hospitals in China, accounting for 44% of
26
27 all tertiary hospitals in the country, had submitted in-patient records to HQMS database.
28
29 Hospitalizations were used in the present analyses since it's more relevant to the
30
31 discussion of "disease burden". This study was approved by the ethics committee of
32
33 Peking University First Hospital (2015-928) and informed consent was waived by the
34
35 ethics committee.
36
37
38
39
40
41

42 *Definition of CKD*

43
44 The ICD-10 coding of discharged diagnoses was used to identify patients with CKD.^{14 15}
45
46 Hospitalizations with at least one of the following diagnoses (in both primary diagnosis
47
48 and secondary diagnoses) were identified as having CKD (relevant ICD-10 coding in
49
50 supplemental appendix 1): glomerulonephritis, diabetic nephropathy, hypertensive
51
52 nephropathy, obstructive nephropathy, renal cancer, tubulointerstitial nephritis, kidney
53
54
55
56
57
58
59
60

1
2
3 disease secondary to autoimmune diseases, kidney failure of unknown reason. Among
4 patient-records with CKD, only 14% of them had the diagnoses of CKD staging.
5
6
7
8
9

10 *Definition of other NCDs*

11 Major NCDs, including coronary heart disease (CHD), stroke, hypertension, diabetes,
12 chronic obstructive pulmonary disease (COPD), and cancer,¹ were identified by the ICD-
13 10 coding of hospital discharge diagnoses (in both primary and secondary diagnoses,
14 relevant ICD-10 coding in supplemental appendix 1). Information on coronary
15 angiography (CAG), percutaneous coronary intervention (PCI), and coronary artery
16 bypass graft was obtained from the procedure coding of the front page for patients with
17 CHD. For patients with multiple NCD diagnoses, each relevant diagnosis was identified
18 and counted when stratified by the above NCDs.
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 *Other covariates*

34 Individual variables including age, sex, occupation (professional, worker, farmer,
35 retirement, unemployment, and others), type of health insurance (basic medical insurance,
36 new rural co-operative medical care, other types of insurance, and uninsured), type of
37 admission (emergency, routine, and others), and intensive care unit (ICU) stay were
38 collected from the front page.
39
40
41
42
43
44
45
46
47
48

49 *Outcomes*

50 Hospitalizations costs and length of hospital stay, which are both important indicators for
51 healthcare resource utilization, were acquired from the front page. Information on in-
52
53
54
55
56
57
58
59
60

1
2
3 hospital mortality was also collected to assess the prognosis of patients. The survival
4 status of each patient was verified based on the discharge status and combined with the
5 information of autopsy.
6
7
8
9

10 11 12 *Statistical analysis*

13
14 General characteristics stratified by the presence of CKD for each NCD were described.
15 Continuous data were presented as mean \pm standard, or as median (inter-quartile range)
16 for highly skewed variables. Categorical variables were presented as proportions. All
17 analyses were based on the hospitalizations (patient-records), not individuals.
18
19
20
21
22

23
24 The effects of CKD on healthcare resource utilization for each NCD were analyzed
25 using generalized linear regression models for log-transformed cost and length-of-stay.
26 Poisson regression model was used to evaluate the impacts of CKD and other NCDs on
27 in-hospital mortality. Percent of change and relative risk (RR) with 95% confidence
28 interval (CI) were reported and calculated as $\exp(\beta)-1$ and $\exp(\beta)$, respectively. For the
29 purpose of accessing additional effects of CKD, covariates included in the model for the
30 sub-dataset of each NCD were age (5-year categories, except for 18-25 years and >80
31 years), sex (male vs. female), type of health insurance (dummy variable), type of
32 admission (dummy variable), ICU stay (yes vs. no), presence of CKD (yes vs. no),
33 presence of other NCDs (yes vs. no), pneumonia (yes vs. no), and sepsis (yes vs. no).
34
35
36
37
38
39
40
41
42
43
44
45
46

47 Then the presence of CKD and other NCDs were included in the models
48 simultaneously, using the data of all hospitalized patients, in order to compare the effect
49 of CKD with other NCDs on outcome variables. Similar covariates were used as
50 described previously.
51
52
53
54
55
56
57
58
59
60

1
2
3 For hospitalized patients with CHD, percentages of CAG and PCI were reported
4 among different clinical types (including ST-segment elevation myocardial infarction,
5 non-ST-segment elevation myocardial infarction, and non-acute coronary syndrome),
6 stratified by the presence of CKD. Among 18,315 hospitalizations with CHD and with
7 diagnoses of CKD staging, percentages of CAG and PCI were also reported.
8
9

10 All analyses were performed using the SAS software, version 9.4 (SAS Institute Inc,
11 Cary, NC). Due to the large sample size of our study, *P* values were not reported for
12 between-group comparison.
13
14

15 *Patient and public involvement statement*

16 Patients or the public were not involved in this study.
17
18
19
20
21
22
23

24 **Results**

25 Among 19.5 million hospitalizations, the percentages of diagnosed CKD, CHD, stroke,
26 hypertension, diabetes, COPD, and cancer were 4.5%, 9.2%, 8.2%, 18.8%, 7.9%, 2.3%,
27 and 19.4%, respectively (table 1). For each major NCD, patient-records with CKD were
28 older (except for hypertension), had a higher percentage of male, urban residents, ICU
29 stay, and infectious diseases such as pneumonia and sepsis (except for COPD).
30
31

32 For each major NCD, the presence of CKD was independently associated with
33 longer hospital stay, with increased percentages ranging from 7.69% (95% CI
34 7.11%~8.28%, for stroke) to 21.60% (95% CI 21.09%~22.10%, for CHD) (table 2). After
35 adjusting for potential confounders, the presence of CKD was associated with higher
36 costs for stroke (11.15%, 95% CI 10.31%~11.99%), COPD (19.46%, 95% CI
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 17.97%~20.97%), and cancer (18.88%, 95% CI 17.98%~19.78%), whereas the costs
4
5 were slightly lower for CHD (acute coronary syndrome or non-acute coronary syndrome)
6
7 (-1.08%, 95% CI -1.71%~-0.45%), hypertension (-0.22%, 95% CI -0.60%~0.16%), and
8
9 diabetes (-0.97%, 95% CI -1.43%~-0.51%) in the presence of CKD (table 2). If patients
10
11 with CHD were excluded, the presence of CKD was associated with increased costs for
12
13 patients with hypertension and diabetes, with a fully adjusted change of 2.70% (95% CI
14
15 2.24%~3.15%) and 4.11% (95% CI 3.56%~4.66%), respectively. The in-hospital
16
17 mortality was also higher in the presence of CKD for major NCDs, with fully adjusted
18
19 RR from 1.91 (95% CI 1.82~1.99, for stroke; 95% CI 1.85~1.97, for hypertension) to
20
21 2.65 (95% CI 2.55~2.75, for cancer) (table 2).

22
23
24
25
26 Among hospitalizations with CHD, the percentages of CAG and PCI were
27
28 substantially lower for those with CKD (figure 1). A similar pattern was observed for
29
30 coronary artery bypass graft, which was 0.3% vs. 1.0% for CHD patients with or without
31
32 CKD. Even for those with acute coronary syndrome or cardiogenic shock, a strong
33
34 indication for emergency PCI,¹⁶ the trend was still similar: 11.9% vs. 22.2% for ST-
35
36 elevated myocardial infarction, and 3.5% vs. 7.3% for non-ST elevated myocardial
37
38 infarction. Furthermore, among hospitalizations with diagnoses of CKD staging and with
39
40 CHD, the percentages of CAG and PCI were lower even for stage 1-2, compared with
41
42 those without CKD and with CHD (figure 1).

43
44
45
46
47 Compared with other NCDs, CKD had the most increase in length of hospital stay
48
49 (22.09%, 95% CI 21.87%~22.32%) (table 3). Cancer and CHD were associated with the
50
51 highest contribution to increased costs for hospitalized patients, which was 39.47% (95%
52
53 CI 39.29%~39.65%) and 30.95% (95% CI 30.71%~31.19%), respectively. CKD was
54
55
56
57
58
59
60

1
2
3 associated with 6.82% (95% CI 6.56%~7.08%) increased costs. Furthermore, CKD
4
5 resulted in the second highest in-hospital mortality (RR of 2.23, 95% CI 2.19~2.28),
6
7 which was only lower than that of cancer (RR of 2.87, 95% CI 2.83~2.91).
8
9

10 11 12 **Discussion**

13
14 This study is the first national quantitative study on the burden of CKD and other major
15
16 NCDs and their impacts on healthcare system in China. The findings of this study
17
18 indicated that the presence of CKD was associated with extra burden on healthcare
19
20 system and increased in-hospital mortality for each major NCD, despite evidence of
21
22 under-utilization of cardiac procedures in the presence of CKD. Furthermore, the impacts
23
24 of CKD on healthcare recourse utilization and mortality were comparable to other major
25
26 NCDs in this large national sample of 19.5 million hospitalizations.
27
28

29
30
31 Studies regarding the utilization of healthcare resources for CKD mostly focused on
32
33 end-stage kidney disease (ESKD).¹⁷⁻¹⁹ The US Renal Data System 2019 Annual Data
34
35 Report showed that costs on both CKD and ESKD were in excess of \$120 billion in 2017,
36
37 and the latter accounted for more than 7.2% of the total Medicare expenditure.²⁰ Our
38
39 study revealed that CKD was associated with a 6.8% increase in costs, which was higher
40
41 than that of hypertension, diabetes, and COPD. Moreover, for each major NCD, the
42
43 presence of CKD led to longer hospital stay, which is also an important marker for
44
45 healthcare resource utilization. Furthermore, considering evidence of therapeutic nihilism
46
47 for patients with CKD (documented for cardiac revascularization) and the insensitivity of
48
49 diagnostic codes for CKD, the impacts of CKD on healthcare system might be
50
51 underestimated. A recent systematic review also showed that risks of adverse
52
53
54
55
56
57
58
59
60

1
2
3 cardiovascular outcomes increased with CKD and are associated with substantial
4
5 additional costs and resource utilization.²¹
6
7

8 Several previous studies reported that both the general and high-risk population have
9
10 worse prognoses in the presence of kidney diseases. For example, using the data of 1.1
11
12 million adults within a large integrated healthcare system, Go AS *et al* observed increased
13
14 risks of all-cause mortality, CVD, and hospitalization associated with reduced kidney
15
16 function.⁹ A recent meta-analysis reported that both reduced estimated glomerular
17
18 filtration rate (eGFR) and elevated urinary albumin-to-creatinine ratio were associated
19
20 with increased all-cause and cardiovascular mortality in the general population.²²
21
22 Similarly, using data from over 40 cohorts involving one million participants, it was
23
24 reported that the adjusted hazard ratio for all-cause mortality at eGFR 45 ml/min/1.73m²
25
26 was 1.24 (95% CI 1.11~1.39) for those with hypertension,²³ and was 1.35 (95% CI
27
28 1.18~1.55) for those with diabetes,²⁴ compared with those with eGFR of 95
29
30 ml/min/1.73m². In this study, we further expanded the observation to a range of other
31
32 major NCDs, including CHD, stroke, COPD, and cancer. We found that CKD was
33
34 consistently associated with increased in-hospital mortality for each major NCD and its
35
36 impact was higher compared with the majority of NCDs, even comparable to that of
37
38 cancer. These findings further highlight the importance of CKD as a major health burden
39
40 and are consistent with the implications of Global Burden of Disease, Injuries, and Risk
41
42 Factors Study, which has showed the high burden and rapid growth of CKD as a direct
43
44 cause of morbidity and mortality.^{5 25}
45
46
47
48
49
50

51 The potential mechanisms for the association of CKD with adverse outcomes are not
52
53 fully understood, although there are several possible explanations. First, a previous study
54
55
56
57
58
59

1
2
3 indicated that impaired kidney function could lead to multiple adverse systemic
4 alterations, including inappropriate activation of the renin-angiotensin system, catalytic
5 iron-dependent oxidative stress, endothelial dysfunction, and inflammation.¹¹
6
7
8 Furthermore, an elevated blood phosphate level accompanied by impaired kidney
9
10 function has been associated with increased cardiovascular risk,²⁶ perhaps through its
11
12 direct effect on vascular calcification,²⁷ as well as through elevated levels of phosphaturic
13
14 hormones such as fibroblast growth factor 23.²⁸ In addition, CKD is associated with
15
16 alterations in primary host defense mechanisms, thus increasing the risk of infection.²⁹
17
18
19 Second, appropriate adjustment of drug dosage according to the kidney function is
20
21 important for reducing medication errors and ensuring optimal patient outcomes.³⁰ In
22
23 developing countries like China, this is aggravated by unmet needs for both hospital and
24
25 community pharmacists.³¹ Finally, for patients whose CKD is a result of systemic disease
26
27 such as diabetes, kidney diseases might only serve as a marker of the severity of the
28
29 target organ damage.
30
31
32
33
34

35 Another explanation for the adverse outcome observed in patients with CKD might
36
37 be that the presence of CKD is associated with reduced implementation of best practice.
38
39 Despite that accumulating evidence and the Kidney Disease: Improving Global Outcomes
40
41 (KDIGO) guidelines with international consensus suggest that the level of care for
42
43 ischemic heart disease offered to patients with CKD should not be prejudiced by their
44
45 CKD,²⁹ our data on revascularization indicates that cardiac treatment for patients with
46
47 CKD is sub-optimal. Under-utilization of aspirin, beta-blockers, angiotensin-converting
48
49 enzyme inhibitors, glycoprotein IIb/IIIa receptor antagonists, and thrombolytic therapy
50
51 has been observed in CKD patients due to concerns of bleeding risk, worsening of kidney
52
53
54
55
56
57
58
59
60

1
2
3 function, and comorbidities.³² A recent study from the United States indicated that
4 compared with those without CKD, patients with CKD reported more medication use for
5 cardiovascular risk factor but had poorer risk factor control.³³ In our study, the
6 percentages of CAG and PCI were much lower for hospitalizations with CKD, even for
7 those with relatively well-preserved kidney function, consistent with practice outside of
8 China.³² A recent meta-analysis revealed that for patients with pre-dialysis CKD and with
9 unstable angina or non-ST segment elevation myocardial infarction, an early invasive
10 strategy was associated with the risk of re-hospitalization and trends of reduction in the
11 risk for death and non-fatal re-infarction.³⁴ However, the risk of adverse clinical events
12 after coronary revascularization and the percentage of later additional PCI were also
13 increased for patients with CKD.^{35 36} Hence, a multi-disciplinary team involving various
14 sub-specialties is needed to improve the quality of care for CKD patients and appropriate
15 management by primary care clinicians are necessary to prevent CKD-associated adverse
16 outcomes.³⁷

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36 To our knowledge, this is the first study that places the CKD burden on hospital stay
37 and mortality in the full context of all major NCDs in a national database with large
38 sample size and wide geographical coverage, which enables us to compare the impacts of
39 multiple major NCDs simultaneously. However, our study does have some limitations.
40 First, although our data are restricted to hospitalized patients, hospitalization inherently
41 reflects indication for admission and referral as well as disease burden. Only tertiary
42 hospitals were included in our analyses, which might lead to population selection bias;
43 but 715 hospitals in our study covered almost all provinces of China and included all
44 types of tertiary hospitals. Second, the diagnosis of CKD and major NCDs in hospitalized
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 patients was based on the ICD-10 coding with low sensitivity. We have performed a
4
5 validation study using data of 67,376 patients from 3 hospitals in HQMS database. The
6
7 sensitivity and specificity of CKD identification by discharge diagnoses were 34.2% and
8
9 97.8%, respectively.³⁸ Severe cases of CKD were likely to be diagnosed, which might
10
11 lead to a potential overestimation of the excess risk associated with CKD. However, the
12
13 high specificity and accuracy of definition for patients with CKD are the strengths of our
14
15 study. Finally, data of eGFR or proteinuria and information on medications used and the
16
17 severity of major NCDs were not available for all patient-records in our dataset.
18
19
20
21
22
23

24 **Conclusions**

25
26 Our study revealed that in a systematic national assessment of diagnosed NCDs over 19.5
27
28 million hospitalizations in China, the adverse effects of CKD at both individual level and
29
30 healthcare system level were comparable to other major NCDs and the presence of CKD
31
32 was associated with poor prognosis of other NCDs. Therefore, CKD should be integrated
33
34 into the global prevention strategy of NCDs. In consideration of the complexity of the
35
36 disease, a multi-level interdisciplinary approach will be needed to address the public
37
38 health burden of CKD.
39
40
41
42
43

44 **Acknowledgments**

45
46 The authors thank the Bureau of Medical Administration and Medical Service
47
48 Supervision, National Health Commission of China for the support of this study.
49
50
51
52
53

54 **Contributors**

1
2
3 HW and LZ conceived and coordinated the study and acquired the data. CY, HW, and LZ
4
5 designed the study. CY and LZ searched the literature. CY and JL prepared the figure.
6
7
8 CY, HW, and LZ wrote the first draft manuscript. CY, JL, SY, and ZZ contributed to the
9
10 analysis. CY, JL, SY, ZZ, JW, M-HZ, HW, LZ, and JC contributed to the interpretation.
11
12
13 CY, JL, SY, ZZ, JW, M-HZ, HW, LZ, and JC edited the manuscript. All authors
14
15 critically reviewed the manuscript and approved the final version.
16
17
18

19 **Funding**

20
21 This study was supported by grants from the National Natural Science Foundation of
22
23 China (82003529, 91846101, 81771938, 81900665, 82090021), Beijing Nova
24
25 Programme Interdisciplinary Cooperation Project (Z191100001119008), National Key
26
27 R&D Program of the Ministry of Science and Technology of China (2019YFC2005000),
28
29 Chinese Scientific and Technical Innovation Project 2030 (2018AAA0102100), the
30
31 University of Michigan Health System-Peking University Health Science Center Joint
32
33 Institute for Translational and Clinical Research (BMU2018JI012, BMU2019JI005),
34
35 CAMS Innovation Fund for Medical Sciences (2019-I2M-5-046), and PKU-Baidu Fund
36
37 (2019BD017).
38
39
40
41
42
43
44

45 **Competing interests**

46
47 LZ received research funding from AstraZeneca. JC was partly supported by grants to the
48
49 CKD Prognosis Consortium by the National Kidney Foundation and NIH.
50
51
52
53

54 **Patient and public involvement statement**

1
2
3 Patients or the public were not involved in this study.
4
5
6
7

8 **Patient consent for publication**

9

10 Not required.
11
12
13

14 **Ethics approval**

15

16 Ethical approval was obtained from the ethics committee of Peking University First
17 Hospital (2015-928).
18
19
20
21
22
23

24 **Data availability statement**

25

26 The data that support the findings of this study are available from the Bureau of Medical
27 Administration and Medical Service Supervision, National Health Commission of China
28 but restrictions apply to the availability of these data, which were used under license for
29 the current study, and so are not publicly available. Data are however available from the
30 authors upon reasonable request and with permission of the Bureau of Medical
31 Administration and Medical Service Supervision, National Health Commission of China.
32
33
34
35
36
37
38
39
40
41

42 **Supplementary material**

43

44 Appendix 1. The International Classification of Diseases-10 coding of chronic kidney
45 disease and other major non-communicable chronic diseases
46
47
48
49
50

51 **ORCID iDs**

52

53 Chao Yang <https://orcid.org/0000-0001-9682-8395>
54
55
56
57
58
59
60

Luxia Zhang <https://orcid.org/0000-0003-2349-2936>

Reference

1. Beaglehole R, Bonita R, Horton R, et al. Priority actions for the non-communicable disease crisis. *Lancet (London, England)* 2011;377(9775):1438-47. doi: 10.1016/s0140-6736(11)60393-0 [published Online First: 2011/04/09]
2. Organization WH. Noncommunicable diseases progress monitor 2020, 2020.
3. Kluge HHP, Wickramasinghe K, Rippin HL, et al. Prevention and control of non-communicable diseases in the COVID-19 response. *Lancet (London, England)* 2020;395(10238):1678-80. doi: 10.1016/s0140-6736(20)31067-9 [published Online First: 2020/05/14]
4. Sheldon TA, Wright J. Twin epidemics of covid-19 and non-communicable disease. *BMJ (Clinical research ed)* 2020;369:m2618. doi: 10.1136/bmj.m2618 [published Online First: 2020/07/02]
5. Collaboration GCKD. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet (London, England)* 2020;395(10225):709-33. doi: 10.1016/S0140-6736(20)30045-3
6. Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. *Lancet (London, England)* 2013;382(9887):158-69. doi: 10.1016/s0140-6736(13)60439-0 [published Online First: 2013/06/04]

- 1
2
3 7. Couser WG, Remuzzi G, Mendis S, et al. The contribution of chronic kidney disease to
4
5 the global burden of major noncommunicable diseases. *Kidney international*
6
7 2011;80(12):1258-70. doi: 10.1038/ki.2011.368 [published Online First:
8
9 2011/10/14]
- 10
11
12 8. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the
13
14 United States. *Jama* 2007;298(17):2038-47. doi: 10.1001/jama.298.17.2038
15
16 [published Online First: 2007/11/08]
- 17
18
19 9. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death,
20
21 cardiovascular events, and hospitalization. *The New England journal of medicine*
22
23 2004;351(13):1296-305. doi: 10.1056/NEJMoa041031 [published Online First:
24
25 2004/09/24]
- 26
27
28 10. Lee M, Saver JL, Chang KH, et al. Low glomerular filtration rate and risk of stroke:
29
30 meta-analysis. *BMJ (Clinical research ed)* 2010;341:c4249. doi:
31
32 10.1136/bmj.c4249 [published Online First: 2010/10/05]
- 33
34
35 11. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney
36
37 disease. A clinical update from Kidney Disease: Improving Global Outcomes
38
39 (KDIGO). *Kidney international* 2011;80(6):572-86. doi: 10.1038/ki.2011.223
40
41 [published Online First: 2011/07/14]
- 42
43
44 12. Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a
45
46 cross-sectional survey. *Lancet (London, England)* 2012;379(9818):815-22. doi:
47
48 10.1016/s0140-6736(12)60033-6 [published Online First: 2012/03/06]
- 49
50
51 13. Yang C, Gao B, Zhao X, et al. Executive summary for China Kidney Disease
52
53 Network (CK-NET) 2016 Annual Data Report. *Kidney international*
54
55

- 2020;98(6):1419-23. doi: 10.1016/j.kint.2020.09.003 [published Online First: 2020/12/06]
14. Zhang L, Long J, Jiang W, et al. Trends in Chronic Kidney Disease in China. *The New England journal of medicine* 2016;375(9):905-6. doi: 10.1056/NEJMc1602469 [published Online First: 2016/09/01]
15. Zhang L, Zhao MH, Zuo L, et al. China Kidney Disease Network (CK-NET) 2016 Annual Data Report. *Kidney international supplements* 2020;10(2):e97-e185. doi: 10.1016/j.kisu.2020.09.001 [published Online First: 2020/12/12]
16. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. *Circulation* 2016;134(10):e123-55. doi: 10.1161/cir.0000000000000404 [published Online First: 2016/03/31]

- 1
2
3 17. Wong CKH, Chen J, Fung SKS, et al. Direct and indirect costs of end-stage renal
4
5 disease patients in the first and second years after initiation of nocturnal home
6
7 haemodialysis, hospital haemodialysis and peritoneal dialysis. *Nephrology,*
8
9 *dialysis, transplantation : official publication of the European Dialysis and*
10
11 *Transplant Association - European Renal Association* 2019;34(9):1565-76. doi:
12
13 10.1093/ndt/gfy395 [published Online First: 2019/01/23]
14
15
16
17 18. Becker BN, Luo J, Gray KS, et al. Association of Chronic Condition Special Needs
18
19 Plan With Hospitalization and Mortality Among Patients With End-Stage Kidney
20
21 Disease. *JAMA network open* 2020;3(11):e2023663. doi:
22
23 10.1001/jamanetworkopen.2020.23663 [published Online First: 2020/11/03]
24
25
26
27 19. Wang V, Vilme H, Maciejewski ML, et al. The Economic Burden of Chronic Kidney
28
29 Disease and End-Stage Renal Disease. *Seminars in nephrology* 2016;36(4):319-
30
31 30. doi: 10.1016/j.semnephrol.2016.05.008 [published Online First: 2016/08/01]
32
33
34
35 20. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 Annual Data
36
37 Report: Epidemiology of Kidney Disease in the United States. *American journal*
38
39 *of kidney diseases : the official journal of the National Kidney Foundation*
40
41 2020;75(1 Suppl 1):A6-a7. doi: 10.1053/j.ajkd.2019.09.003 [published Online
42
43 First: 2019/11/11]
44
45
46
47 21. Darlington O, Dickerson C, Evans M, et al. Costs and Healthcare Resource Use
48
49 Associated with Risk of Cardiovascular Morbidity in Patients with Chronic
50
51 Kidney Disease: Evidence from a Systematic Literature Review. *Advances in*
52
53 *therapy* 2021 doi: 10.1007/s12325-020-01607-4 [published Online First:
54
55 2021/01/13]
56
57
58
59
60

- 1
2
3 22. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular
4
5 filtration rate and albuminuria with all-cause and cardiovascular mortality in
6
7 general population cohorts: a collaborative meta-analysis. *Lancet (London,*
8
9 *England)* 2010;375(9731):2073-81. doi: 10.1016/s0140-6736(10)60674-5
10
11 [published Online First: 2010/05/21]
12
13
14
15 23. Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease
16
17 measures with mortality and end-stage renal disease in individuals with and
18
19 without hypertension: a meta-analysis. *Lancet (London, England)*
20
21 2012;380(9854):1649-61. doi: 10.1016/s0140-6736(12)61272-0 [published
22
23 Online First: 2012/09/28]
24
25
26 24. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures
27
28 with mortality and end-stage renal disease in individuals with and without
29
30 diabetes: a meta-analysis. *Lancet (London, England)* 2012;380(9854):1662-73.
31
32 doi: 10.1016/s0140-6736(12)61350-6 [published Online First: 2012/09/28]
33
34
35 25. Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life
36
37 lost, and all-cause and cause-specific mortality for 250 causes of death: reference
38
39 and alternative scenarios for 2016-40 for 195 countries and territories. *Lancet*
40
41 *(London, England)* 2018;392(10159):2052-90. doi: 10.1016/s0140-
42
43 6736(18)31694-5 [published Online First: 2018/10/21]
44
45
46
47 26. Hruska K, Mathew S, Lund R, et al. Cardiovascular risk factors in chronic kidney
48
49 disease: does phosphate qualify? *Kidney international Supplement*
50
51 2011;79(121):S9-13. doi: 10.1038/ki.2011.24 [published Online First: 2011/02/25]
52
53
54
55
56
57
58
59
60

- 1
2
3 27. London GM. Mechanisms of arterial calcifications and consequences for
4
5 cardiovascular function. *Kidney international supplements* 2013;3(5):442-45. doi:
6
7 10.1038/kisup.2013.92 [published Online First: 2014/07/16]
8
9
10 28. Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in
11
12 cardiovascular disease. *Nature reviews Nephrology* 2014;10(5):268-78. doi:
13
14 10.1038/nrneph.2014.49 [published Online First: 2014/04/02]
15
16
17 29. Stevens PE, Levin A. Evaluation and management of chronic kidney disease:
18
19 synopsis of the kidney disease: improving global outcomes 2012 clinical practice
20
21 guideline. *Annals of internal medicine* 2013;158(11):825-30. doi: 10.7326/0003-
22
23 4819-158-11-201306040-00007 [published Online First: 2013/06/05]
24
25
26 30. Bhardwaja B, Carroll NM, Raebel MA, et al. Improving prescribing safety in patients
27
28 with renal insufficiency in the ambulatory setting: the Drug Renal Alert Pharmacy
29
30 (DRAP) program. *Pharmacotherapy* 2011;31(4):346-56. doi:
31
32 10.1592/phco.31.4.346 [published Online First: 2011/04/01]
33
34
35 31. Wang J, Wang P, Wang X, et al. Use and prescription of antibiotics in primary health
36
37 care settings in China. *JAMA internal medicine* 2014;174(12):1914-20. doi:
38
39 10.1001/jamainternmed.2014.5214 [published Online First: 2014/10/07]
40
41
42 32. Cai Q, Mukku VK, Ahmad M. Coronary artery disease in patients with chronic
43
44 kidney disease: a clinical update. *Current cardiology reviews* 2013;9(4):331-9.
45
46 doi: 10.2174/1573403x10666140214122234 [published Online First: 2014/02/18]
47
48
49 33. Foster MC, Rawlings AM, Marrett E, et al. Cardiovascular risk factor burden,
50
51 treatment, and control among adults with chronic kidney disease in the United
52
53
54
55
56
57
58
59
60

- 1
2
3 States. *American heart journal* 2013;166(1):150-6. doi: 10.1016/j.ahj.2013.03.016
4
5 [published Online First: 2013/07/03]
6
7
8 34. Charytan DM, Wallentin L, Lagerqvist B, et al. Early angiography in patients with
9
10 chronic kidney disease: a collaborative systematic review. *Clinical journal of the*
11
12 *American Society of Nephrology : CJASN* 2009;4(6):1032-43. doi:
13
14 10.2215/cjn.05551008 [published Online First: 2009/05/09]
15
16
17 35. Ix JH, Mercado N, Shlipak MG, et al. Association of chronic kidney disease with
18
19 clinical outcomes after coronary revascularization: the Arterial Revascularization
20
21 Therapies Study (ARTS). *American heart journal* 2005;149(3):512-9. doi:
22
23 10.1016/j.ahj.2004.10.010 [published Online First: 2005/05/03]
24
25
26 36. Kaneko H, Yajima J, Oikawa Y, et al. Role of arterial stiffness and impaired renal
27
28 function in the progression of new coronary lesions after percutaneous coronary
29
30 intervention. *Cardiovascular intervention and therapeutics* 2013;28(1):56-62. doi:
31
32 10.1007/s12928-012-0135-y [published Online First: 2012/09/27]
33
34
35 37. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and
36
37 Management: A Review. *Jama* 2019;322(13):1294-304. doi:
38
39 10.1001/jama.2019.14745 [published Online First: 2019/10/02]
40
41
42 38. Huang YM, Xu D, Long J, et al. Spectrum of chronic kidney disease in China: A
43
44 national study based on hospitalized patients from 2010 to 2015. *Nephrology*
45
46 *(Carlton, Vic)* 2019;24(7):725-36. doi: 10.1111/nep.13489 [published Online First:
47
48 2018/09/11]
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 1. Percentages of coronary angiography and percutaneous coronary**
4 **intervention for hospitalizations with coronary heart disease**
5
6
7
8
9

10
11 Note: The number of hospitalizations with or without CKD was 3,116 and 68,616 for
12 STEMI, 2,645 and 25,057 for NSTEMI, 124,388 and 1,519,864 for NACS, respectively.
13 For 18,315 hospitalizations with diagnoses of CKD staging, 15.8%, 24.6%, 16.8%, and
14
15
16
17
18
19 42.9% of them were in stage 1-2, 3, 4 and 5.

20 Abbreviations: CKD, chronic kidney disease; NACS, non-acute coronary syndrome;
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
elevation myocardial infarction.

Table 1. Characteristics of hospitalized patients with non-communicable chronic diseases stratified by the presence of chronic kidney disease

	CHD		Stroke		Hypertension		Diabetes		COPD		Cancer		Total	
	CKD	Non-CKD	CKD	Non-CKD	CKD	Non-CKD	CKD	Non-CKD	CKD	Non-CKD	CKD	Non-CKD	CKD	Non-CKD
Number	132032	1665601	79 906	1529843	348075	3322665	222157	1321816	22998	429475	80285	3698423	871742	18647248
Percentage (%)	0.7	8.5	0.4	7.8	1.8	17.0	1.1	6.8	0.1	2.2	0.2	19.0	4.5	95.5
Age (years)	71.4±11.8	68.1±12.0	69.1±13.0	65.9±12.9	64.7±14.3	65.7±12.3	63.7±13.2	63.3±12.8	76.7±9.6	72.8±10.3	62.4±13.8	56.7±13.3	57.7±17.0	52.7±17.6
Male (%)	60.2	55.4	62.6	55.1	59.4	52.2	57.6	53.1	76.6	71.7	60.2	49.7	57.3	45.6
Occupation (%)†														
Professional	7.6	8.7	8.0	8.5	9.8	9.2	11.0	11.2	4.2	4.2	10.1	11.1	11.9	14.4
Worker	4.9	5.3	5.6	5.9	5.9	5.9	6.5	6.3	3.8	4.7	6.6	6.2	6.6	7.1
Farmer	11.8	18.1	15.7	23.0	15.6	19.1	14.7	15.8	15.2	23.2	17.1	24.7	21.3	21.5
Retirement	40.9	32.4	36.6	27.7	30.6	28.7	31.0	28.3	42.3	31.3	22.8	14.5	20.7	13.8
Unemployment	7.0	6.3	7.1	7.4	8.6	7.3	8.7	7.4	7.5	7.8	8.8	9.7	9.4	10.1
Others	27.8	29.4	27.0	27.4	29.5	29.9	28.2	31.1	27.1	28.9	33.0	33.7	30.2	33.1
Health insurance (%)														
Basic medical insurance	66.0	59.0	62.7	54.0	59.6	57.0	62.3	59.9	63.1	54.3	50.9	43.0	49.9	42.9
NRCMC	12.5	18.7	15.8	22.6	16.9	19.4	15.8	16.7	15.5	24.4	19.8	26.7	23.2	22.5
Others	11.0	11.6	9.8	10.3	10.6	10.3	9.9	10.3	10.2	10.0	11.3	12.7	11.4	13.0
Uninsured	10.5	10.8	11.8	13.1	12.9	13.3	12.0	13.1	11.2	11.3	18.0	17.6	15.4	21.6
Admission (%)†														
Emergency	21.6	22.6	25.3	29.3	17.3	20.5	16.5	16.9	22.9	23.1	16.9	7.4	16.1	17.9
Routine	71.6	69.4	68.3	63.2	76.0	72.2	76.6	75.1	69.1	68.9	80.0	82.4	76.0	72.6
Others	6.8	7.9	6.5	7.6	6.7	7.4	6.9	8.0	8.0	8.0	8.0	10.2	7.9	9.5
ICU stay (%)	4.1	3.0	3.9	2.7	2.4	2.0	2.2	1.7	5.1	3.2	2.2	0.7	2.0	1.2
Hypertension (%)	69.6	55.3	71.1	56.6	--	--	62.7	52.6	54.8	33.6	33.3	12.2	39.9	17.8
CHD (%)	--	--	28.2	18.7	26.4	27.7	26.8	25.8	35.9	23.0	23.0	2.9	15.2	8.9
Stroke (%)	17.1	17.1	--	--	16.3	26.0	14.8	18.9	12.7	9.5	12.7	1.8	9.2	8.2
COPD (%)	6.2	5.9	3.7	2.7	3.6	4.3	2.6	3.1	--	--	11.1	1.1	2.6	2.3
Cancer (%)	5.7	6.5	4.9	4.4	7.5	13.5	5.0	13.4	7.9	9.6	11.1	--	9.2	19.8
Diabetes (%)	45.0	20.5	41.2	16.3	40.0	20.9	--	--	24.6	9.6	11.1	4.8	25.5	7.1
Pneumonia (%)	6.1	4.1	5.8	3.6	4.3	3.6	4.3	3.4	8.3	8.5	11.1	2.0	3.7	2.3
Sepsis (%)	0.5	0.2	0.7	0.2	0.5	0.2	0.7	0.3	0.7	0.3	0.7	0.2	0.6	0.2
Costs (1000 yuan)	11(7-20)	9(6-20)	11(7-19)	9(6-16)	10(6-17)	9(6-16)	10(7-16)	9(6-16)	12(8-22)	10(6-16)	15(5-29)	10(6-20)	9(6-17)	8(4-14)
Length-of-stay (days)†	11(8-17)	9(6-13)	12(8-17)	11(7-15)	11(7-16)	9(6-14)	12(8-16)	10(7-14)	12(8-19)	10(7-15)	12(6-19)	8(4-14)	11(6-16)	8(5-13)
Mortality (%)	3.5	1.4	3.5	1.5	1.8	0.9	1.8	0.9	4.9	1.9	5.3	1.0	1.8	0.6

1
2
3
4
5
6 †The percentages of missing values for occupation, type of admission and length of stay was 10.9%, 6.4%, and 16.6% for CHD;
7
8 10.5%, 7.1%, and 17.5% for stroke; 10.7%, 6.7%, and 16.2% for hypertension; 10.7%, 6.9%, and 16.6% for diabetes; 12.2%, 5.4%,
9
10 and 18.0% for COPD; 11.4%, 6.1%, and 15.2% for cancer.

11
12
13 Abbreviations: CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ICU,
14
15 intensive care unit; NCDs, non-communicable chronic diseases; NRCMC, New Rural Co-operative Medical Care.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 2. Effects of chronic kidney disease on length of stay, costs, and in-hospital mortality for each non-communicable disease

Condition	Covariates in the model	Length of stay % change (95% CI)	Costs % change (95% CI)	In-hospital mortality relative risk (95% CI)
CHD	Model 1	24.58 (24.1, 25.06)	4.96 (4.34, 5.58)	1.15 (2.08, 2.22)
	Model 2	21.99 (21.49, 22.5)	-0.26 (-0.90, 0.37)	1.09 (2.02, 2.16)
	Model 3	21.60 (21.09, 22.10)	-1.08 (-1.71, -0.45)	1.02 (1.95, 2.09)
Stroke	Model 1	11.35 (10.80, 11.90)	16.65 (15.81, 17.49)	1.17 (2.08, 2.26)
	Model 2	8.26 (7.68, 8.85)	13.05 (12.19, 13.91)	1.01 (1.92, 2.10)
	Model 3	7.69 (7.11, 8.28)	11.15 (10.31, 11.99)	1.09 (1.82, 1.99)
Hypertension	Model 1	14.46 (14.17, 14.74)	-0.40 (-0.76, -0.04)	1.04 (1.89, 2.00)
	Model 2	16.24 (15.92, 16.55)	0.49 (0.10, 0.87)	1.07 (1.91, 2.03)
	Model 3	16.01 (15.70, 16.33)	-0.22 (-0.60, 0.16)	1.09 (1.85, 1.97)
Diabetes	Model 1	14.05 (13.70, 14.41)	-2.90 (-3.33, -2.47)	1.08 (1.82, 1.95)
	Model 2	16.55 (16.16, 16.94)	-0.14 (-0.60, 0.33)	1.02 (1.94, 2.10)
	Model 3	16.32 (15.93, 16.70)	-0.97 (-1.43, -0.51)	1.05 (1.88, 2.03)
COPD	Model 1	15.85 (14.84, 16.87)	31.41 (29.78, 33.06)	1.21 (2.08, 2.35)
	Model 2	11.14 (10.11, 12.18)	20.15 (18.65, 21.68)	1.09 (1.86, 2.13)
	Model 3	11.05 (10.02, 12.09)	19.46 (17.97, 20.97)	1.07 (1.84, 2.11)
Cancer	Model 1	21.38 (20.66, 22.11)	25.84 (24.96, 26.72)	1.30 (3.19, 3.41)
	Model 2	17.87 (17.11, 18.64)	19.63 (18.72, 20.54)	1.07 (2.65, 2.85)
	Model 3	17.50 (16.74, 18.26)	18.88 (17.98, 19.78)	1.06 (2.55, 2.75)

Note: Numbers in the table are percent-changes/relative risks of patient-record with CKD compared with patient-record without CKD for each non-communicable disease.

1
2
3
4
5 Covariates in model 1 included age and sex.

6
7 Covariates in model 2 included age, sex, occupation, type of health insurance, type of admission, intensive care unit stay, presence of
8
9 CHD, stroke, hypertension, diabetes, COPD, and cancer (except for the disease used to define the subgroup).

10
11 Covariates in model 3 included covariates in model 2, plus the presence of sepsis and pneumonia.

12
13
14 Abbreviations: CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive
15
16 pulmonary disease.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 3. Effects of chronic kidney disease on length of stay, costs, and in-hospital mortality - comparisons with other major non-communicable diseases

Condition	Covariates in the model	Length of stay % change (95% CI)	Costs % change (95% CI)	In-hospital mortality relative risk (95% CI)
CKD	Model 1	22.34 (22.14, 22.55)	6.49 (6.25, 6.73)	2.31 (2.27, 2.35)
	Model 2	22.09 (21.87, 22.32)	6.82 (6.56, 7.08)	2.23 (2.19, 2.28)
CHD	Model 1	-5.19 (-5.31, -5.07)	27.72 (27.51, 27.94)	1.36 (1.34, 1.38)
	Model 2	-7.31 (-7.44, -7.18)	30.95 (30.71, 31.19)	1.31 (1.29, 1.33)
Stroke	Model 1	16.12 (15.97, 16.27)	9.29 (9.10, 9.48)	1.58 (1.56, 1.60)
	Model 2	17.34 (17.17, 17.51)	9.90 (9.69, 10.11)	1.70 (1.67, 1.73)
Hypertension	Model 1	5.49 (5.39, 5.59)	8.90 (8.77, 9.04)	1.93 (0.92, 0.94)
	Model 2	1.81 (1.69, 1.92)	4.85 (4.70, 5.01)	1.76 (0.75, 0.77)
Diabetes	Model 1	11.36 (11.22, 11.51)	5.05 (4.87, 5.23)	1.13 (1.11, 1.15)
	Model 2	8.96 (8.80, 9.12)	1.00 (0.81, 1.20)	1.99 (0.97, 1.01)
COPD	Model 1	3.89 (3.65, 4.14)	-9.00 (-9.29, -8.71)	1.31 (1.28, 1.34)
	Model 2	5.77 (5.50, 6.04)	-8.67 (-8.98, -8.36)	1.24 (1.21, 1.27)
Cancer	Model 1	8.90 (8.80, 9.00)	27.40 (27.25, 27.55)	2.00 (1.97, 2.02)
	Model 2	13.90 (13.79, 14.02)	39.47 (39.29, 39.65)	2.87 (2.83, 2.91)

Note: Numbers in the table are percent-changes/relative risks of patient-record with corresponding disease compared with patient-record without corresponding disease.

1
2
3
4
5 Covariates in model 1 included age and sex.

6
7 Covariates in model 2 included age, sex, occupation, type of health insurance, type of admission, intensive care unit stay, presence of
8
9 CKD, CHD, stroke, hypertension, diabetes, COPD, and cancer, and presence of sepsis and pneumonia.

10
11 Abbreviations: CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive
12
13 pulmonary disease.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47




Figure 1. Percentages of coronary angiography and percutaneous coronary intervention for hospitalizations with coronary heart disease

Note: The number of hospitalizations with or without CKD was 3,116 and 68,616 for STEMI, 2,645 and 25,057 for NSTEMI, 124,388 and 1,519,864 for NACS, respectively. For 18,315 hospitalizations with diagnoses of CKD staging, 15.8%, 24.6%, 16.8%, and 42.9% of them were in stage 1-2, 3, 4 and 5.

Abbreviations: CKD, chronic kidney disease; NACS, non-acute coronary syndrome; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.

227x170mm (300 x 300 DPI)

Appendix 1. The International Classification of Diseases-10 coding of chronic kidney disease and other major non-communicable chronic diseases

Disease	ICD-10 coding
CKD	E10.2+, E11.2+, E13.2+, E14.2+, I12.0, I12.9, I13.0, I13.1, I13.2, I13.9, N11, N12, N14, N15, N16.* , E74.8, E72.0, N25.1, M32.1+N08.5*, M32.1+N16.4* , M35.0+N16.4* , M31.0+N08.5* , M31.7+N08.5* , M31.001‡, M31.802‡, M32.101+N08.5*†, M31.102+N08.5*†, M31.303+N08.5*†, N18, N19, N13.0, N13.1, N13.2, C64, N07, N08 (excluding N08.5*), N13.6, Q60, Q61.1, Q61.2, Q61.3, Q61.5, Q63.1, Q63.9, M10.3, N26, N28.0, N28.8, N28.9, A52.7+N08.0* , N99.0, P96.0, R39.2, K76.7, Q27.1, I70.1, M31.4 (combined with I15.0) E10.2+, E11.2+, E13.2+, E14.2+ N00.8, N02, N03, N04, N05, N06, N39.1
CHD	I21.001, I21.002, I21.004, I21.101, I21.103, I21.104, I21.105, I21.201, I21.202, I21.203, I21.204, I21.205, I21.206, I21.207, I21.208, I21.209, I21.210, I21.211, I21.213, I21.214, I21.215, I21.301, I21.302, I21.304, I21.907, I21.403, I24.803, I20.001, I20.002, I20.003, I20.004, I20.005, I20.006, I20.101, I20.102, I20.802, I20.803, I21.303, I21.401, I21.402, I21.901, I21.902, I21.910, I22.001, I22.101, I22.801, I22.802, I22.803, I22.901, I23.001, I23.002, I23.101, I23.201, I23.301, I24.001, I24.002, I24.003, I24.004, I24.005, I24.006, I24.101, I24.102, I24.801, I24.802, I24.901, I20.801, I20.804, I20.805, I20.806, I20.902, I25.103, I25.104, I25.105, I25.201, I25.202, I25.203, I25.204, I25.205, I25.206, I25.207, I25.208, I25.209, I25.210, I25.211, I25.212, I25.213, I25.214, I25.215, I25.501, I25.601, I25.901, I25.902
CHD‡	I21.000, I21.001, I21.002, I21.003, I21.004, I21.005, I21.006, I21.007, I21.100, I21.101, I21.102, I21.103, I21.104, I21.105, I21.200, I21.201, I21.202, I21.203, I21.204, I21.205, I21.206, I21.300, I21.301, I21.401, I20.000, I20.001, I20.002, I20.003, I20.004, I20.005, I20.006, I20.100, I20.101, I20.102, I20.804, I21.302, I21.303, I21.400, I21.402, I21.900, I22.000, I22.100, I22.800, I22.900, I23.000, I23.100, I23.200, I23.300, I23.400, I23.500, I23.600, I23.601, I23.800, I24.000, I24.001, I24.100, I24.101, I24.800, I24.801, I24.900, I24.901, I20.801, I20.802, I20.803, I20.804, I20.900, I25.000, I25.100, I25.101, I25.102, I25.103, I25.200, I25.500, I25.600, I25.800, I25.801, I25.900, I25.901,
COPD	J44.901†, J44.003†, J44.103†, J44.900‡, J44.000‡, J44.100‡, J44.800‡
Stroke	I60, I61, I63, I64, G45, H34.1
Cancer	C00-C26, C30-C34, C37-C41, C43-C58, C60-C85, C88, C90-C97, D00-D07, D09, D37-D48, B21, Z85, Z00 Z51.10†, Z51.20†, Z51.50†, Z03.101†, E87.805†, O99.8011†, O99.8021†, O99.8024†, O99.8031†, Z51.00‡, Z51.10‡, Z51.80‡, Z03.10‡, O99.802‡, Z35.802‡, Z54.001‡, E88.805‡, Z86.000‡
Hypertension	I10

Disease	ICD-10 coding
Sepsis	A41
Pneumonia	J12-J18

†Applicable for ICD-10 (Beijing Version 4.0) only.

‡Applicable for ICD-10 (National Standard Version1.0) only.

Abbreviations: CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary diseases. ICD-10, International Classification of Diseases-10.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6-7
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-10
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	-
		(d) If applicable, describe analytical methods taking account of sampling strategy	10
		(e) Describe any sensitivity analyses	-
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11
		(b) Indicate number of participants with missing data for each variable of interest	-
Outcome data	15*	Report numbers of outcome events or summary measures	11-13

BMJ Open

Impacts of chronic kidney disease and other major non-communicable chronic diseases on healthcare resource utilization in China: a cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-051888.R1
Article Type:	Original research
Date Submitted by the Author:	28-Sep-2021
Complete List of Authors:	Yang, Chao; Peking University First Hospital, Long, Jianyan; First Affiliated Hospital of Sun Yat-Sen University, Clinical Trial Unit Shi, Ying; China Standard Medical Information Research Center Zhou, Zhiye; China Standard Medical Information Research Center Wang, Jinwei; Peking University First Hospital Zhao, Ming-Hui; Peking University Institute of Nephrology, Renal Division Wang, Haibo; First Affiliated Hospital of Sun Yat-Sen University; National Institute of Health Data Science at Peking University Zhang, Luxia; Peking University First Hospital; National Institute of Health Data Science at Peking University Coresh, J; Johns Hopkins University Bloomberg School of Public Health, Department of Epidemiology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Epidemiology, Renal medicine, Public health, Cardiovascular medicine, Diabetes and endocrinology
Keywords:	Public health < INFECTIOUS DISEASES, Epidemiology < TROPICAL MEDICINE, Chronic renal failure < NEPHROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Impacts of chronic kidney disease and other major non-communicable**
4 **chronic diseases on healthcare resource utilization in China: a cross-**
5 **sectional study**
6
7
8
9

10 Running head: CKD and NCDs in China
11
12
13

14
15
16 Chao Yang, MS^{1,2,7}; Jianyan Long, MSc³; Ying Shi, BMS⁴; Zhiye Zhou, MSc⁴; Jinwei
17 Wang, PhD^{1,2}; Ming-Hui Zhao, MD^{1,2,5}; Haibo Wang, MBBS, MSc, MPH^{3,6,*}; Luxia
18 Zhang, MD, MPH^{1,6,7,*}; Josef Coresh, MD, PhD⁸
19
20
21
22

23
24
25 ¹*Renal Division, Department of Medicine, Peking University First Hospital, Peking*
26 *University Institute of Nephrology, Beijing, China*
27

28
29 ²*Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases,*
30 *Chinese Academy of Medical Sciences, Beijing, China*
31

32
33
34 ³*Clinical Trial Unit, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,*
35 *Guangdong, China*
36

37
38
39 ⁴*China Standard Medical Information Research Center, Shenzhen, Guangdong, China*
40

41
42 ⁵*Peking-Tsinghua Center for Life Sciences, Beijing, China*
43

44
45 ⁶*National Institute of Health Data Science at Peking University, Beijing, China*
46

47
48
49 ⁷*Advanced Institute of Information Technology, Peking University, Hangzhou, Zhejiang,*
50 *China*
51

52
53
54 ⁸*Department of Epidemiology, Johns Hopkins University Bloomberg School of Public*
55 *Health, Baltimore, MD, USA*
56
57
58
59
60

1
2
3 ***Corresponding authors:** Luxia Zhang, MD, MPH, Renal Division, Department of
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Medicine, Peking University First Hospital, Peking University Institute of Nephrology,
No. 8, Xishiku Street, Xicheng District, Beijing 100034, China. Phone: +86-10-8357-
5817, Fax: +86-10-6655-1055, E-mail: zhanglx@bjmu.edu.cn; Haibo Wang, MBBS,
MSc, MPH, Clinical Trial Unit, First Affiliated Hospital of Sun Yat-Sen University,
Guangzhou 510080, China; Phone: +86-755-3331-9080, Fax: +86-755-3331-9061, E-
mail: haibo@mail.harvard.edu.

Abstract

Objective: To evaluate the impacts of chronic kidney disease (CKD) and other major non-communicable chronic diseases (NCDs) on healthcare system in China.

Design: A cross-sectional study.

Setting: A national inpatient database in tertiary hospitals in China.

Participants: A total of 19.5 million hospitalizations of adult patients from July, 2013 to June, 2014. Information on CKD and other major NCDs, including coronary heart disease (CHD), stroke, hypertension, diabetes, chronic obstructive pulmonary disease (COPD), and cancer was extracted from the unified discharge summary form.

Outcome measures: Costs, length of hospital stay, and in-hospital mortality.

Results: The percentages of hospitalizations with CKD, CHD, stroke, hypertension, diabetes, COPD, and cancer were 4.5%, 9.2%, 8.2%, 18.8%, 7.9%, 2.3%, and 19.4%, respectively. For each major NCD, the additional presence of CKD was independently associated with longer hospital stay, with increased percentages ranging from 7.69% (95% confidence interval [CI], 7.11%–8.28%) for stroke to 21.60% (95% CI, 21.09%–22.10%) for CHD. The hospital mortality for other NCDs was also higher in the presence of CKD, with fully adjusted relative risk ranging from 1.91 (95% CI, 1.82–1.99) for stroke to 2.65 (95% CI, 2.55–2.75) for cancer. Compared with other NCDs, CKD was associated with the longest hospital stay (22.1% increase) and resulted in the second highest in-hospital mortality, only lower than that of cancer (relative risk, 2.23 vs. 2.87, respectively).

Conclusions: The presence of diagnosed CKD alongside each major NCD was associated with an additional burden on the healthcare system. The impacts of CKD on

1
2
3 healthcare resource utilization and prognosis were comparable to those of other major
4
5 NCDs, which highlights the importance of CKD as a major public health burden.
6
7
8
9

10 **Keywords**

11
12 Chronic kidney disease; Disease burden; Health care costs; Length of stay; Mortality;

13
14 Non-communicable chronic disease
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- The first national study placing the CKD burden on hospital stay and mortality in the full context of all major NCDs.
- Large sample size and wide geographical coverage.
- Only tertiary hospitals were included, which might have led to population selection bias.
- Diagnosis of major NCDs was based on the ICD-10 coding with low sensitivity.
- Data of eGFR or proteinuria and information on medications were not available.

Background

There is a rising burden of non-communicable diseases (NCDs) at a global level. Two of three deaths each year are attributable to NCDs, and four-fifths of NCD-related deaths occur in low- and middle-income countries.¹ This exerts a significant influence on healthcare system and costs worldwide.² Taking action against NCDs is, therefore, an economic imperative.³ The priority actions for the NCD crisis were released by the United Nations High-Level Meeting in 2011, focusing on the prevention and control of heart disease, stroke, cancer, diabetes, and chronic respiratory diseases.¹ The world leaders also committed to reduce premature deaths from NCDs by one-third by 2030.³

Over the past decade, chronic kidney disease (CKD) has been recognized as a major public health issue worldwide, with an estimated prevalence of more than 10%.^{4,5} By 2040, CKD is estimated to become the fifth leading cause of early death globally—one of the largest projected increases of any major cause of death.⁶ In China, CKD is prevalent and is associated with more severe comorbidities and higher medical expenditures.^{7,8} However, unlike other NCDs, such as diabetes, the awareness of CKD is low among patients and healthcare providers.⁹ Besides, CKD is a key determinant of poor health outcomes of major NCDs and a risk multiplier in patients with cardiovascular disease (CVD), diabetes, and hypertension.¹⁰ Due to the fact that the kidneys are usually target organs of systemic vascular, hemodynamic, metabolic, and inflammatory disorders, the pandemic of NCDs also leads to a persistently increasing morbidity of CKD.¹¹ There is accumulating evidence that major NCDs, including heart disease and stroke, have a poor prognosis in the presence of CKD.¹²⁻¹⁴ Moreover, CKD has been reported to be associated with reduced implementation of best clinical practice, which could lead to suboptimal

1
2
3 treatment and adverse outcomes, especially for patients with CVD.¹⁵
4

5 Although CKD is a global health issue, to the best of our knowledge, there have
6 been neither large-scale studies to quantitatively evaluate the burden of CKD on all major
7 NCDs, nor studies comparing the burden of CKD with other NCDs. The evidence for the
8 impacts of CKD and other major NCDs on the healthcare system at a national level is
9 limited, which impedes the development of effective preventive strategies. In addition,
10 little is known about the status of cardiac procedures for patients with CKD in China.
11 Hence, we initiated this observational study to comprehensively and quantitatively
12 evaluate the impact of CKD on healthcare resource utilization and prognosis of other
13 NCDs, as well as to compare the burden of kidney diseases on the healthcare system with
14 other NCDs among hospitalized patients in China.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Methods**

31 *Study population*

32
33 The Hospital Quality Monitoring System (HQMS) is a mandatory patient-level national
34 database for hospital accreditation under the authority of the National Health
35 Commission of the People's Republic of China. Details of HQMS have been described
36 elsewhere.^{16 17} In brief, all tertiary hospitals in China have been requested to submit
37 electronic inpatient discharge records to HQMS on a daily basis. Unlike the Western
38 medical system, tertiary hospitals in China provide primary, secondary, and tertiary care
39 and have exposure to nationwide patient population. Patient-level data were collected
40 from uniform front pages of hospitalization medical records. Altogether 353 variables
41 including demographic characteristics, clinical diagnoses, procedures, pathology
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 diagnoses, and expenditure breakdowns were collected. All personal information has
4 already been de-identified to protect patient privacy. The diagnoses were coded based on
5 the International Classification of Diseases-10 (ICD-10) coding system by certified
6 professional medical coders at every hospital. As the part of stringent standard practice in
7 China, the front page has the legal validity and must be filed by the care-giving doctors
8 who have the most accurate and comprehensive understanding of the patient's medical
9 condition.

10
11
12 A total of 19,518,990 records of adult inpatients admitted from July 1, 2013 to June
13 30, 2014 in 29 provinces (excluding Hong Kong, Macao, Taiwan, Tibet, and Ningxia)
14 were included in this cross-sectional study, with certain patients having more than one
15 hospitalization. During this period, 715 tertiary hospitals in China, accounting for 44% of
16 all tertiary hospitals in the country, had submitted inpatient records to HQMS database.
17 Hospitalizations were used in the present analysis since they are more relevant to the
18 discussion of "disease burden".¹⁸ This study was approved by the Ethics Committee of
19 Peking University First Hospital (2015-928) and informed consent was waived by the
20 Ethics Committee.

21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Definition of CKD

The ICD-10 coding of discharge diagnoses was used to identify patients with CKD.^{16 17}
Hospitalizations of patients with at least one of the following diagnoses (in both primary
diagnosis and secondary diagnoses) were identified as having CKD (relevant ICD-10
coding in supplemental Appendix 1): glomerulonephritis, diabetic nephropathy,
hypertensive nephropathy, obstructive nephropathy, renal cancer, tubulointerstitial

1
2
3 nephritis, kidney disease secondary to autoimmune diseases, kidney failure of unknown
4
5 reason. Among patients' records with CKD, only 14% of them had the information on
6
7 CKD staging.
8
9

10 11 12 13 14 *Validation study*

15
16
17
18 Since the laboratory results are not included in the HQMS dataset, we performed a
19
20 validation study using 67,376 hospitalizations in three hospitals in the HQMS. Those
21
22 were the pilot hospitals that accomplished the HQMS phase 2 data collection expansion
23
24 to the data of laboratory tests and medications.¹⁹ The estimated glomerular filtration rate
25
26 (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) Study
27
28 equation tailored for Chinese CKD patients.²⁰ Proteinuria was defined by urinary
29
30 albumin-to-creatinine ratio (ACR) ≥ 30 mg/g creatinine, and/or urinary protein \geq trace in
31
32 urine routine test. CKD was defined as the presence of proteinuria and/or eGFR less than
33
34 60 ml/min/1.73 m². Compared with the gold standard, the sensitivity and specificity of
35
36 CKD identification by ICD-10 coding was 34.2% and 97.8%, respectively.¹⁹
37
38
39
40
41
42
43

44 *Definition of other NCDs*

45
46 Major NCDs, including coronary heart disease (CHD), stroke, hypertension, diabetes,
47
48 chronic obstructive pulmonary disease (COPD), and cancer,¹ were identified by the ICD-
49
50 10 coding of hospital discharge diagnoses (in both primary and secondary diagnoses,
51
52 relevant ICD-10 coding in supplemental Appendix 1). Information on coronary
53
54 angiography (CAG), percutaneous coronary intervention (PCI), and coronary artery
55
56
57
58
59
60

bypass grafting was obtained from the procedure coding of the front page for patients with CHD. For patients with multiple NCD diagnoses, each relevant diagnosis was identified and counted when stratified by the above NCDs.

Other covariates

Individual variables including age, sex, occupation (professional, worker, farmer, retired, unemployed, and others), type of health insurance (basic medical insurance, new rural cooperative medical care, other types of insurance, and uninsured), type of admission (emergency, routine, and others), and intensive care unit (ICU) stay were collected from the front page.

Outcomes

Hospitalization costs and length of hospital stay, which are both important indicators for healthcare resource utilization, were acquired from the front page. The total costs of the patient's hospitalization were jointly borne by the patient, the government, and related insurers, and included costs for prescribed drugs, hospital beds, laboratory tests, medical examinations, and surgical costs. Information on in-hospital mortality was also collected to assess the prognosis of patients. The survival status of each patient was verified based on the discharge status and combined with the information of autopsy.

Statistical analysis

General characteristics stratified by the presence of CKD for each NCD were described. Continuous data were presented as mean \pm standard deviation, or as median (interquartile

range) for highly skewed variables. Categorical variables were presented as proportions. All of the analyses were based on the hospitalizations (patient records), not individuals.

The effects of CKD on healthcare resource utilization for each NCD were analyzed using generalized linear regression models for log-transformed cost and length of stay. Poisson regression model was used to evaluate the impacts of CKD and other NCDs on in-hospital mortality. Percent of change and relative risk (RR) with 95% confidence interval (CI) were reported and calculated as $\exp(\beta)-1$ and $\exp(\beta)$, respectively. For the purpose of assessing additional effects of CKD, covariates included in the model for the sub-dataset of each NCD were age (5-year categories, except for 18–25 years and >80 years), sex (male vs. female), type of health insurance (dummy variable), type of admission (dummy variable), ICU stay (yes vs. no), presence of CKD (yes vs. no), presence of other NCDs (yes vs. no), pneumonia (yes vs. no), and sepsis (yes vs. no).

Then, the presence of CKD and other NCDs was included in the models simultaneously, using the data of all hospitalized patients, in order to compare the effect of CKD with that of other NCDs on outcome variables. Similar covariates were used as described previously.

For hospitalized patients with CHD, percentages of those with CAG and PCI were reported among different clinical types (including ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, and non-acute coronary syndrome), stratified by the presence of CKD. Among 18,315 hospitalizations with CHD and with available CKD staging, the percentages of those with CAG and PCI were also reported.

The sensitivity analysis was conducted among patients with CKD stages 3-5 to

1
2
3 further determine the impacts of CKD on healthcare resource utilization (Appendices 2
4 and 3). All analyses were performed using the SAS software, version 9.4 (SAS Institute
5 Inc, Cary, NC). Due to the large sample size of our study, *P* values were not reported for
6
7
8
9
10 between-group comparisons.

11 12 13 14 15 *Patient and public involvement statement*

16
17 Patients or the public were not involved in this study.
18
19
20

21 22 **Results**

23
24 Among 19.5 million hospitalizations, the percentages of diagnosed CKD, CHD, stroke,
25
26 hypertension, diabetes, COPD, and cancer were 4.5%, 9.2%, 8.2%, 18.8%, 7.9%, 2.3%,
27
28 and 19.4%, respectively (table 1). For each major NCD, individuals with CKD were older
29
30 (except for hypertension); were more often male and urban residents; more often stayed
31
32 in ICU and had infectious diseases such as pneumonia and sepsis (except for COPD).
33
34

35
36 For each major NCD, the presence of CKD was independently associated with
37
38 longer hospital stay, with increased percentages ranging from 7.69% (95% CI, 7.11%–
39
40 8.28%, for stroke) to 21.60% (95% CI, 21.09%–22.10%, for CHD) (Table 2). After
41
42 adjusting for potential confounders, the presence of CKD was associated with higher
43
44 costs for stroke (11.15%; 95% CI, 10.31%–11.99%), COPD (19.46%; 95% CI, 17.97%–
45
46 20.97%), and cancer (18.88%; 95% CI, 17.98%–19.78%). In contrast, the costs were
47
48 slightly lower for CHD (acute coronary syndrome or non-acute coronary syndrome)
49
50 (–1.08%; 95% CI, –1.71% to –0.45%), hypertension (–0.22%; 95% CI, –0.60% to
51
52 0.16%), and diabetes (–0.97%; 95% CI, –1.43% to –0.51%) in the presence of CKD
53
54
55
56
57
58
59
60

(Table 2). If patients with CHD were excluded, the presence of CKD was associated with increased costs for patients with hypertension and diabetes, with a fully adjusted change of 2.70% (95% CI, 2.24%–3.15%) and 4.11% (95% CI, 3.56%–4.66%), respectively. The in-hospital mortality was also higher in the presence of CKD for major NCDs, with fully adjusted RR ranging from 1.91 (95% CI, 1.82–1.99, for stroke; 95% CI, 1.85–1.97, for hypertension) to 2.65 (95% CI, 2.55–2.75, for cancer) (Table 2).

Among hospitalizations with CHD, the percentages of individuals with CAG and PCI were substantially lower for those with CKD (Figure 1). A similar pattern was observed for coronary artery bypass grafting, which was 0.3% and 1.0% for CHD patients with or without CKD, respectively. Even for those with acute coronary syndrome or cardiogenic shock—a strong indication for emergency PCI²¹—the trend was still similar: 11.9% vs. 22.2% for ST-elevated myocardial infarction, and 3.5% vs. 7.3% for non-ST elevated myocardial infarction. Furthermore, among hospitalizations with available CKD staging and with CHD, the percentages of individuals with CAG and PCI were lower even for stage 1 and 2, compared with those without CKD and with CHD (Figure 1).

Compared with other NCDs, CKD had the highest increase in length of hospital stay (22.09%; 95% CI, 21.87%–22.32%) (Table 3). Cancer and CHD were associated with the highest contribution to increased costs for hospitalized patients, which was 39.47% (95% CI, 39.29%–39.65%) and 30.95% (95% CI, 30.71%–31.19%), respectively. CKD was associated with 6.82% (95% CI, 6.56%–7.08%) increased costs. Furthermore, CKD resulted in the second highest in-hospital mortality (RR, 2.23; 95% CI, 2.19–2.28), which was only lower than that of cancer (RR, 2.87; 95% CI, 2.83–2.91).

Discussion

This study is the first national quantitative study on the burden of CKD and other major NCDs and their impacts on the healthcare system in China. The findings of this study indicated that the presence of CKD was associated with additional burden on the healthcare system and increased in-hospital mortality for each major NCD, despite evidence of under-utilization of cardiac procedures in the presence of CKD. Furthermore, the impacts of CKD on healthcare resource utilization and mortality were comparable to those of other major NCDs in this large national sample of 19.5 million hospitalizations.

Studies regarding the utilization of healthcare resources for CKD mostly focused on end-stage kidney disease (ESKD).²²⁻²⁴ The US Renal Data System 2019 Annual Data Report showed that the costs for both CKD and ESKD were in excess of \$120 billion in 2017, and the latter accounted for more than 7.2% of the total Medicare expenditure.²⁵ Our study revealed that CKD was associated with a 6.8% increase in costs, which was higher than that of hypertension, diabetes, and COPD. Moreover, for each major NCD, the presence of CKD led to longer hospital stay, which is also an important marker for healthcare resource utilization. Furthermore, considering the evidence of therapeutic nihilism for patients with CKD (documented for cardiac revascularization) and the insensitivity of diagnostic codes for CKD, the impacts of CKD on the healthcare system might be underestimated. A recent systematic review has also shown that the risks of adverse cardiovascular outcomes increase with CKD and are associated with substantial additional costs and resource utilization.²⁶

Several previous studies have reported that both the general and high-risk

1
2
3 populations have poor prognoses in the presence of kidney diseases. For example, using
4 the data of 1.1 million adults within a large integrated healthcare system, Go *et al.*
5
6 observed increased risks of all-cause mortality, CVD, and hospitalization associated with
7
8 reduced kidney function.¹² A recent meta-analysis has reported that both reduced eGFR
9
10 and elevated urinary albumin-to-creatinine ratio are associated with increased all-cause
11
12 and cardiovascular mortality in the general population.²⁷ Similarly, using data from over
13
14 40 cohorts involving one million participants, it has been reported that the adjusted
15
16 hazard ratio for all-cause mortality at an eGFR of 45 ml/min/1.73 m² was 1.24 (95% CI,
17
18 1.11–1.39) for those with hypertension,²⁸ and was 1.35 (95% CI 1.18–1.55) for those with
19
20 diabetes,²⁹ compared with those with eGFR of 95 ml/min/1.73 m². In this study, we
21
22 further expanded the observation to a range of other major NCDs, including CHD, stroke,
23
24 COPD, and cancer. We found that CKD was consistently associated with increased in-
25
26 hospital mortality for each major NCD, and its impact was higher compared with that of
27
28 the majority of NCDs, even comparable to that of cancer. These findings further highlight
29
30 the importance of CKD as a major health burden and are consistent with the implications
31
32 of Global Burden of Disease, Injuries, and Risk Factors Study, which has shown the high
33
34 burden and rapid growth of CKD as a direct cause of morbidity and mortality.^{4,6}
35
36
37
38
39
40
41

42 The potential mechanisms for the association of CKD and adverse outcomes are
43
44 complex and not fully understood. A previous study indicated that impaired kidney
45
46 function could lead to multiple adverse systemic alterations, including inappropriate
47
48 activation of the renin-angiotensin system, catalytic iron-dependent oxidative stress,
49
50 endothelial dysfunction, and inflammation.¹⁴ In addition, for patients whose CKD is a
51
52 result of a systemic disease such as diabetes, kidney diseases might only serve as a
53
54
55
56
57
58
59
60

1
2
3 marker of the severity of the target organ damage.
4

5 Another explanation for the adverse outcomes observed in patients with CKD might
6 be that the presence of CKD is associated with reduced implementation of best practice.
7
8 Although the accumulating evidence and the Kidney Disease: Improving Global
9
10 Outcomes (KDIGO) guidelines with international consensus suggest that the level of care
11
12 for ischemic heart disease offered to patients with CKD should not be prejudiced by their
13
14 CKD,³⁰ our data on revascularization indicate that cardiac treatment for patients with
15
16 CKD is suboptimal. Under-utilization of aspirin, beta-blockers, angiotensin-converting
17
18 enzyme inhibitors, glycoprotein IIb/IIIa receptor antagonists, and thrombolytic therapy
19
20 has been observed in CKD patients due to concerns of bleeding risk, worsening of kidney
21
22 function, and comorbidities.¹⁵ A recent study from the United States indicated that,
23
24 compared with those without CKD, patients with CKD reported more medication use for
25
26 cardiovascular risk factors but had poorer risk factor control.³¹ In our study, the
27
28 percentages of hospitalizations with CAG and PCI were much lower for those with CKD,
29
30 even for those with relatively well-preserved kidney function, consistent with the practice
31
32 outside of China.¹⁵ A recent meta-analysis has revealed that for patients with pre-dialysis
33
34 CKD and with unstable angina or non-ST-segment-elevation myocardial infarction, an
35
36 early invasive strategy is associated with the risk of re-hospitalization and reduced risk of
37
38 death and non-fatal re-infarction.³² However, the risk of adverse clinical events after
39
40 coronary revascularization and the percentage of later additional PCI are also increased in
41
42 patients with CKD.^{33 34} Hence, a multidisciplinary team involving various subspecialties
43
44 is needed to improve the quality of care for CKD patients, and appropriate management
45
46 by primary care clinicians is necessary to prevent CKD-associated adverse outcomes.³⁵
47
48
49
50
51
52
53
54
55
56
57
58
59
60

To our knowledge, this is the first study that places the CKD burden on hospital stay and mortality in the full context of all major NCDs in a national database with large sample size and wide geographical coverage, which enables us to analyze the impacts of multiple major NCDs simultaneously. However, our study does have some limitations. First, although our data were restricted to hospitalized patients, hospitalization inherently reflects indication for admission and referral as well as disease burden. Only tertiary hospitals were included in our analyses, which might have led to population selection bias; nevertheless, 715 hospitals in our study covered almost all provinces of China and included all types of tertiary hospitals. Second, the diagnosis of CKD and major NCDs in hospitalized patients was based on the ICD-10 coding, which has low sensitivity. Severe cases of CKD were likely to be diagnosed, which might affect the extrapolation of the results and lead to a potential overestimation of the excess risk associated with CKD. However, the high specificity of CKD identification (97.8%) is the strength of our study. Third, the low usage of CKD-staging codes was a limitation that should be recognized. Further evaluation of the healthcare utilization in different CKD stages is worthwhile. Fourth, since hospitalizations were identified using both primary and secondary diagnoses, the direct contribution of specific NCDs to health resource utilization might have been compromised. All of the analyses were based on the hospitalizations, and cases reported in the results were not mutually exclusive, which may also affect the estimations of the true burden of disease. Finally, data on eGFR or proteinuria and information on medications used and the severity of major NCDs were not available for all patient records in our dataset.

Conclusions

In a systematic national assessment of diagnosed NCDs over 19.5 million hospitalizations in China, we showed that the adverse effects of CKD at both individual level and healthcare system level were comparable to those of other major NCDs, and the presence of CKD was associated with poor prognosis of other NCDs. Therefore, CKD should be integrated into the global prevention strategy of NCDs. In consideration of the complexity of the disease, a multilevel interdisciplinary approach will be needed to address the public health burden of CKD.

Acknowledgments

The authors thank the Bureau of Medical Administration and Medical Service Supervision, National Health Commission of China for the support of this study.

Contributors

HW and LZ conceived and coordinated the study and acquired the data. CY, HW, and LZ designed the study. CY and LZ searched the literature. CY and JL prepared the figure. CY, HW, and LZ wrote the first draft manuscript. CY, JL, SY, and ZZ contributed to the analysis. CY, JL, SY, ZZ, JW, M-HZ, HW, LZ, and JC contributed to the interpretation. CY, JL, SY, ZZ, JW, M-HZ, HW, LZ, and JC edited the manuscript. All authors critically reviewed the manuscript and approved the final version.

Funding

This study was supported by grants from the National Natural Science Foundation of

1
2
3 China (82003529, 91846101, 81771938, 81900665, 82090021), Beijing Nova
4
5 Programme Interdisciplinary Cooperation Project (Z191100001119008), National Key
6
7 R&D Program of the Ministry of Science and Technology of China (2019YFC2005000),
8
9 Chinese Scientific and Technical Innovation Project 2030 (2018AAA0102100), the
10
11 University of Michigan Health System-Peking University Health Science Center Joint
12
13 Institute for Translational and Clinical Research (BMU2018JI012, BMU2019JI005,
14
15 71017Y2027), CAMS Innovation Fund for Medical Sciences (2019-I2M-5-046), and
16
17 PKU-Baidu Fund (2019BD017, 2020BD032).
18
19
20
21
22
23

24 **Competing interests**

25
26 JC was partly supported by grants to the CKD Prognosis Consortium by the National
27
28 Kidney Foundation and NIH.
29
30
31
32

33 **Patient and public involvement statement**

34
35 Patients or the public were not involved in this study.
36
37
38
39

40 **Patient consent for publication**

41
42 Not required.
43
44
45
46

47 **Ethics approval**

48
49 Ethical approval was obtained from the Ethics Committee of Peking University First
50
51 Hospital (2015-928).
52
53
54
55
56
57
58
59
60

Data availability statement

The data that support the findings of this study are available from the Bureau of Medical Administration and Medical Service Supervision, National Health Commission of China but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the Bureau of Medical Administration and Medical Service Supervision, National Health Commission of China.

Supplementary material

Appendix 1. The International Classification of Diseases-10 coding of chronic kidney disease and other major non-communicable chronic diseases

Appendix 2. Effects of chronic kidney disease stages 3-5 on length of stay, costs, and in-hospital mortality for each non-communicable disease

Appendix 3. Effects of chronic kidney disease stages 3-5 on length of stay, costs, and in-hospital mortality, compared with other major non-communicable diseases

ORCID iDs

Chao Yang <https://orcid.org/0000-0001-9682-8395>

Luxia Zhang <https://orcid.org/0000-0003-2349-2936>

Reference

1. Beaglehole R, Bonita R, Horton R, et al. Priority actions for the non-communicable disease crisis. *Lancet (London, England)* 2011;377(9775):1438-47. doi: 10.1016/s0140-6736(11)60393-0 [published Online First: 2011/04/09]
2. Hunter DJ, Reddy KS. Noncommunicable diseases. *The New England journal of medicine* 2013;369(14):1336-43. doi: 10.1056/NEJMra1109345 [published Online First: 2013/10/04]
3. Organization WH. Noncommunicable diseases progress monitor 2020, 2020.
4. Collaboration GCKD. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet (London, England)* 2020;395(10225):709-33. doi: 10.1016/S0140-6736(20)30045-3
5. Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. *Lancet (London, England)* 2013;382(9887):158-69. doi: 10.1016/s0140-6736(13)60439-0 [published Online First: 2013/06/04]
6. Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. *Lancet (London, England)* 2018;392(10159):2052-90. doi: 10.1016/s0140-6736(18)31694-5 [published Online First: 2018/10/21]

- 1
2
3 7. Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a
4
5 cross-sectional survey. *Lancet (London, England)* 2012;379(9818):815-22. doi:
6
7 10.1016/s0140-6736(12)60033-6 [published Online First: 2012/03/06]
8
9
- 10 8. Yang C, Gao B, Zhao X, et al. Executive summary for China Kidney Disease Network
11
12 (CK-NET) 2016 Annual Data Report. *Kidney international* 2020;98(6):1419-23.
13
14 doi: 10.1016/j.kint.2020.09.003 [published Online First: 2020/12/06]
15
16
- 17 9. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and
18
19 perspectives. *Lancet (London, England)* 2013;382(9888):260-72. doi:
20
21 10.1016/s0140-6736(13)60687-x [published Online First: 2013/06/04]
22
23
- 24 10. Couser WG, Remuzzi G, Mendis S, et al. The contribution of chronic kidney disease
25
26 to the global burden of major noncommunicable diseases. *Kidney international*
27
28 2011;80(12):1258-70. doi: 10.1038/ki.2011.368 [published Online First:
29
30 2011/10/14]
31
32
- 33 11. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the
34
35 United States. *Jama* 2007;298(17):2038-47. doi: 10.1001/jama.298.17.2038
36
37 [published Online First: 2007/11/08]
38
39
- 40 12. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death,
41
42 cardiovascular events, and hospitalization. *The New England journal of medicine*
43
44 2004;351(13):1296-305. doi: 10.1056/NEJMoa041031 [published Online First:
45
46 2004/09/24]
47
48
- 49 13. Lee M, Saver JL, Chang KH, et al. Low glomerular filtration rate and risk of stroke:
50
51 meta-analysis. *BMJ (Clinical research ed)* 2010;341:c4249. doi:
52
53 10.1136/bmj.c4249 [published Online First: 2010/10/05]
54
55
56
57
58
59

- 1
2
3 14. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney
4 disease. A clinical update from Kidney Disease: Improving Global Outcomes
5 (KDIGO). *Kidney international* 2011;80(6):572-86. doi: 10.1038/ki.2011.223
6
7 [published Online First: 2011/07/14]
8
9
10
11
12 15. Cai Q, Mukku VK, Ahmad M. Coronary artery disease in patients with chronic
13 kidney disease: a clinical update. *Current cardiology reviews* 2013;9(4):331-9.
14 doi: 10.2174/1573403x10666140214122234 [published Online First: 2014/02/18]
15
16
17
18
19 16. Zhang L, Long J, Jiang W, et al. Trends in Chronic Kidney Disease in China. *The*
20 *New England journal of medicine* 2016;375(9):905-6. doi:
21
22 10.1056/NEJMc1602469 [published Online First: 2016/09/01]
23
24
25
26 17. Zhang L, Zhao MH, Zuo L, et al. China Kidney Disease Network (CK-NET) 2016
27 Annual Data Report. *Kidney international supplements* 2020;10(2):e97-e185. doi:
28
29 10.1016/j.kisu.2020.09.001 [published Online First: 2020/12/12]
30
31
32
33 18. Hirode G, Saab S, Wong RJ. Trends in the Burden of Chronic Liver Disease Among
34 Hospitalized US Adults. *JAMA network open* 2020;3(4):e201997. doi:
35
36 10.1001/jamanetworkopen.2020.1997 [published Online First: 2020/04/03]
37
38
39
40 19. Huang YM, Xu D, Long J, et al. Spectrum of chronic kidney disease in China: A
41 national study based on hospitalized patients from 2010 to 2015. *Nephrology*
42 *(Carlton, Vic)* 2019;24(7):725-36. doi: 10.1111/nep.13489 [published Online First:
43
44 2018/09/11]
45
46
47
48
49 20. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating
50 equation for Chinese patients with chronic kidney disease. *Journal of the*
51
52
53
54
55
56
57
58
59
60

- 1
2
3 *American Society of Nephrology* : *JASN* 2006;17(10):2937-44. doi:
4
5 10.1681/asn.2006040368 [published Online First: 2006/09/22]
6
7
8 21. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on
9
10 Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease:
11
12 A Report of the American College of Cardiology/American Heart Association
13
14 Task Force on Clinical Practice Guidelines: An Update of the 2011
15
16 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011
17
18 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012
19
20 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and
21
22 Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA
23
24 Guideline for the Management of ST-Elevation Myocardial Infarction, 2014
25
26 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation
27
28 Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative
29
30 Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac
31
32 Surgery. *Circulation* 2016;134(10):e123-55. doi: 10.1161/cir.0000000000000404
33
34 [published Online First: 2016/03/31]
35
36
37
38
39
40 22. Wong CKH, Chen J, Fung SKS, et al. Direct and indirect costs of end-stage renal
41
42 disease patients in the first and second years after initiation of nocturnal home
43
44 haemodialysis, hospital haemodialysis and peritoneal dialysis. *Nephrology,*
45
46 *dialysis, transplantation : official publication of the European Dialysis and*
47
48 *Transplant Association - European Renal Association* 2019;34(9):1565-76. doi:
49
50 10.1093/ndt/gfy395 [published Online First: 2019/01/23]
51
52
53
54
55
56
57
58
59
60

- 1
2
3 23. Becker BN, Luo J, Gray KS, et al. Association of Chronic Condition Special Needs
4
5 Plan With Hospitalization and Mortality Among Patients With End-Stage Kidney
6
7 Disease. *JAMA network open* 2020;3(11):e2023663. doi:
8
9 10.1001/jamanetworkopen.2020.23663 [published Online First: 2020/11/03]
10
11
12 24. Wang V, Vilme H, Maciejewski ML, et al. The Economic Burden of Chronic Kidney
13
14 Disease and End-Stage Renal Disease. *Seminars in nephrology* 2016;36(4):319-
15
16 30. doi: 10.1016/j.semnephrol.2016.05.008 [published Online First: 2016/08/01]
17
18
19 25. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 Annual Data
20
21 Report: Epidemiology of Kidney Disease in the United States. *American journal*
22
23 *of kidney diseases : the official journal of the National Kidney Foundation*
24
25 2020;75(1 Suppl 1):A6-a7. doi: 10.1053/j.ajkd.2019.09.003 [published Online
26
27 First: 2019/11/11]
28
29
30
31 26. Darlington O, Dickerson C, Evans M, et al. Costs and Healthcare Resource Use
32
33 Associated with Risk of Cardiovascular Morbidity in Patients with Chronic
34
35 Kidney Disease: Evidence from a Systematic Literature Review. *Advances in*
36
37 *therapy* 2021 doi: 10.1007/s12325-020-01607-4 [published Online First:
38
39 2021/01/13]
40
41
42 27. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular
43
44 filtration rate and albuminuria with all-cause and cardiovascular mortality in
45
46 general population cohorts: a collaborative meta-analysis. *Lancet (London,*
47
48 *England)* 2010;375(9731):2073-81. doi: 10.1016/s0140-6736(10)60674-5
49
50 [published Online First: 2010/05/21]
51
52
53
54
55
56
57
58
59
60

- 1
2
3 28. Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease
4
5 measures with mortality and end-stage renal disease in individuals with and
6
7 without hypertension: a meta-analysis. *Lancet (London, England)*
8
9 2012;380(9854):1649-61. doi: 10.1016/s0140-6736(12)61272-0 [published
10
11 Online First: 2012/09/28]
12
13
14
15 29. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures
16
17 with mortality and end-stage renal disease in individuals with and without
18
19 diabetes: a meta-analysis. *Lancet (London, England)* 2012;380(9854):1662-73.
20
21 doi: 10.1016/s0140-6736(12)61350-6 [published Online First: 2012/09/28]
22
23
24 30. Stevens PE, Levin A. Evaluation and management of chronic kidney disease:
25
26 synopsis of the kidney disease: improving global outcomes 2012 clinical practice
27
28 guideline. *Annals of internal medicine* 2013;158(11):825-30. doi: 10.7326/0003-
29
30 4819-158-11-201306040-00007 [published Online First: 2013/06/05]
31
32
33 31. Foster MC, Rawlings AM, Marrett E, et al. Cardiovascular risk factor burden,
34
35 treatment, and control among adults with chronic kidney disease in the United
36
37 States. *American heart journal* 2013;166(1):150-6. doi: 10.1016/j.ahj.2013.03.016
38
39 [published Online First: 2013/07/03]
40
41
42 32. Charytan DM, Wallentin L, Lagerqvist B, et al. Early angiography in patients with
43
44 chronic kidney disease: a collaborative systematic review. *Clinical journal of the*
45
46 *American Society of Nephrology : CJASN* 2009;4(6):1032-43. doi:
47
48 10.2215/cjn.05551008 [published Online First: 2009/05/09]
49
50
51 33. Ix JH, Mercado N, Shlipak MG, et al. Association of chronic kidney disease with
52
53 clinical outcomes after coronary revascularization: the Arterial Revascularization
54
55
56
57
58
59
60

- 1
2
3 Therapies Study (ARTS). *American heart journal* 2005;149(3):512-9. doi:
4 10.1016/j.ahj.2004.10.010 [published Online First: 2005/05/03]
5
6
7
8 34. Kaneko H, Yajima J, Oikawa Y, et al. Role of arterial stiffness and impaired renal
9 function in the progression of new coronary lesions after percutaneous coronary
10 intervention. *Cardiovascular intervention and therapeutics* 2013;28(1):56-62. doi:
11 10.1007/s12928-012-0135-y [published Online First: 2012/09/27]
12
13
14
15 35. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and
16 Management: A Review. *Jama* 2019;322(13):1294-304. doi:
17 10.1001/jama.2019.14745 [published Online First: 2019/10/02]
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 1. Percentages of hospitalizations with coronary angiography and**
4 **percutaneous coronary intervention for individuals with coronary heart disease**
5
6
7
8
9

10
11 Note: The number of hospitalizations with or without CKD was 3,116 and 68,616 for
12 STEMI, respectively; 2,645 and 25,057 for NSTEMI, respectively; and 124,388 and
13 1,519,864 for NACS, respectively. For 18,315 hospitalizations with available CKD
14 staging, 15.8%, 24.6%, 16.8%, and 42.9% of individuals were in stages 1–2, 3, 4, and 5,
15
16
17
18
19
20 respectively.

21
22 Abbreviations: CKD, chronic kidney disease; NACS, non-acute coronary syndrome;
23
24 NSTEMI, non-ST-segment-elevation myocardial infarction; STEMI, ST-segment-
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
elevation myocardial infarction.

Table 1. Characteristics of hospitalized patients with non-communicable chronic diseases stratified by the presence of chronic kidney disease

	CHD		Stroke		Hypertension		Diabetes		COPD		Cancer		Total	
	CKD	Non-CKD	CKD	Non-CKD	CKD	Non-CKD	CKD	Non-CKD	CKD	Non-CKD	CKD	Non-CKD	CKD	Non-CKD
Number	132032	1665601	79 906	1529843	348075	3322665	222157	1321816	22998	429475	25585	3698423	871742	18647248
Percentage (%)	0.7	8.5	0.4	7.8	1.8	17.0	1.1	6.8	0.1	2.2	0.4	19.0	4.5	95.5
Main outcomes														
Costs (1000 yuan)	11 (7-20)	9 (6-20)	11 (7-19)	9 (6-16)	10 (6-17)	9 (6-16)	10 (7-16)	9 (6-16)	12 (8-22)	10 (6-16)	11 (7-29)	10 (6-20)	9 (6-17)	8 (4-14)
Length of stay (days) †	11 (8-17)	9 (6-13)	12 (8-17)	11 (7-15)	11 (7-16)	9 (6-14)	12 (8-16)	10 (7-14)	12 (8-19)	10 (7-15)	11 (7-19)	8 (4-14)	11 (6-16)	8 (5-13)
Mortality (%)	3.5	1.4	3.5	1.5	1.8	0.9	1.8	0.9	4.9	1.9	5.0	1.0	1.8	0.6
Demographic characteristics														
Age (years)	71.4±11.8	68.1±12.0	69.1±13.0	65.9±12.9	64.7±14.3	65.7±12.3	63.7±13.2	63.3±12.8	76.7±9.6	72.8±10.3	67.1±13.8	56.7±13.3	57.7±17.0	52.7±17.6
Male (%)	60.2	55.4	62.6	55.1	59.4	52.2	57.6	53.1	76.6	71.7	63.4	49.7	57.3	45.6
Occupation (%) †														
Professional	7.6	8.7	8.0	8.5	9.8	9.2	11.0	11.2	4.2	4.2	4.4	11.1	11.9	14.4
Worker	4.9	5.3	5.6	5.9	5.9	5.9	6.5	6.3	3.8	4.7	6.2	6.2	6.6	7.1
Farmer	11.8	18.1	15.7	23.0	15.6	19.1	14.7	15.8	15.2	23.2	7.6	24.7	21.3	21.5
Retired	40.9	32.4	36.6	27.7	30.6	28.7	31.0	28.3	42.3	31.3	5.3	14.5	20.7	13.8
Unemployed	7.0	6.3	7.1	7.4	8.6	7.3	8.7	7.4	7.5	7.8	8.6	9.7	9.4	10.1
Others	27.8	29.4	27.0	27.4	29.5	29.9	28.2	31.1	27.1	28.9	1.9	33.7	30.2	33.1
Health insurance (%)														
Basic medical insurance	66.0	59.0	62.7	54.0	59.6	57.0	62.3	59.9	63.1	54.3	11.2	43.0	49.9	42.9
NRCMC	12.5	18.7	15.8	22.6	16.9	19.4	15.8	16.7	15.5	24.4	9.8	26.7	23.2	22.5
Others	11.0	11.6	9.8	10.3	10.6	10.3	9.9	10.3	10.2	10.0	3.6	12.7	11.4	13.0
Uninsured	10.5	10.8	11.8	13.1	12.9	13.3	12.0	13.1	11.2	11.3	5.5	17.6	15.4	21.6
Admission and comorbidity information														
Admission (%) †														
Emergency	21.6	22.6	25.3	29.3	17.3	20.5	16.5	16.9	22.9	23.1	0.8	7.4	16.1	17.9
Routine	71.6	69.4	68.3	63.2	76.0	72.2	76.6	75.1	69.1	68.9	0.1	82.4	76.0	72.6
Others	6.8	7.9	6.5	7.6	6.7	7.4	6.9	8.0	8.0	8.0	9.2	10.2	7.9	9.5
ICU stay (%)	4.1	3.0	3.9	2.7	2.4	2.0	2.2	1.7	5.1	3.2	1.0	0.7	2.0	1.2
Hypertension (%)	69.6	55.3	71.1	56.6	--	--	62.7	52.6	54.8	33.6	32.3	12.2	39.9	17.8
CHD (%)	--	--	28.2	18.7	26.4	27.7	26.8	25.8	35.9	23.0	8.4	2.9	15.2	8.9
Stroke (%)	17.1	17.1	--	--	16.3	26.0	14.8	18.9	12.7	9.5	4.8	1.8	9.2	8.2
COPD (%)	6.2	5.9	3.7	2.7	3.6	4.3	2.6	3.1	--	--	2.2	1.1	2.6	2.3
Cancer (%)	5.7	6.5	4.9	4.4	7.5	13.5	5.0	13.4	7.9	9.6	--	--	9.2	19.8

136/bmjopen-2021-05888 on 13 January 2022. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

Diabetes (%)	45.0	20.5	41.2	16.3	40.0	20.9	--	--	24.6	9.6	33.7	4.8	25.5	7.1
Pneumonia (%)	6.1	4.1	5.8	3.6	4.3	3.6	4.3	3.4	8.3	8.5	5.7	2.0	3.7	2.3
Sepsis (%)	0.5	0.2	0.7	0.2	0.5	0.2	0.7	0.3	0.7	0.3	0.6	0.2	0.6	0.2

†The percentages of missing values for occupation, type of admission, and length of stay were 10.9%, 6.4%, and 16.6% for CHD; 10.5%, 7.1%, and 17.5% for stroke; 10.7%, 6.7%, and 16.2% for hypertension; 10.7%, 6.9%, and 16.6% for diabetes; 12.2%, 5.4%, and 18.0% for COPD; and 11.4%, 6.1%, and 15.2% for cancer.

Abbreviations: CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; NCDs, non-communicable chronic diseases; NRCMC, New Rural Cooperative Medical Care.

Table 2. Effects of chronic kidney disease on length of stay, costs, and in-hospital mortality for each non-communicable disease

Condition	Covariates in the model	Length of stay % change (95% CI)	Costs % change (95% CI)	In-hospital mortality relative risk (95% CI)
CHD	Model 1	24.58 (24.1, 25.06)	4.96 (4.34, 5.58)	1.15 (2.08, 2.22)
	Model 2	21.99 (21.49, 22.5)	-0.26 (-0.90, 0.37)	1.09 (2.02, 2.16)
	Model 3	21.60 (21.09, 22.10)	-1.08 (-1.71, -0.45)	1.02 (1.95, 2.09)
Stroke	Model 1	11.35 (10.80, 11.90)	16.65 (15.81, 17.49)	1.17 (2.08, 2.26)
	Model 2	8.26 (7.68, 8.85)	13.05 (12.19, 13.91)	1.01 (1.92, 2.10)
	Model 3	7.69 (7.11, 8.28)	11.15 (10.31, 11.99)	1.01 (1.82, 1.99)
Hypertension	Model 1	14.46 (14.17, 14.74)	-0.40 (-0.76, -0.04)	1.04 (1.89, 2.00)
	Model 2	16.24 (15.92, 16.55)	0.49 (0.10, 0.87)	1.07 (1.91, 2.03)
	Model 3	16.01 (15.70, 16.33)	-0.22 (-0.60, 0.16)	1.01 (1.85, 1.97)
Diabetes	Model 1	14.05 (13.70, 14.41)	-2.90 (-3.33, -2.47)	1.08 (1.82, 1.95)
	Model 2	16.55 (16.16, 16.94)	-0.14 (-0.60, 0.33)	1.02 (1.94, 2.10)
	Model 3	16.32 (15.93, 16.70)	-0.97 (-1.43, -0.51)	1.05 (1.88, 2.03)
COPD	Model 1	15.85 (14.84, 16.87)	31.41 (29.78, 33.06)	1.21 (2.08, 2.35)
	Model 2	11.14 (10.11, 12.18)	20.15 (18.65, 21.68)	1.09 (1.86, 2.13)
	Model 3	11.05 (10.02, 12.09)	19.46 (17.97, 20.97)	1.07 (1.84, 2.11)
Cancer	Model 1	21.38 (20.66, 22.11)	25.84 (24.96, 26.72)	1.30 (3.19, 3.41)
	Model 2	17.87 (17.11, 18.64)	19.63 (18.72, 20.54)	1.07 (2.65, 2.85)
	Model 3	17.50 (16.74, 18.26)	18.88 (17.98, 19.78)	1.06 (2.55, 2.75)

Note: Numbers in the table are percent-changes/relative risks of patient records with CKD compared with patient records without CKD for each non-communicable disease.

1
2
3
4
5 Covariates in model 1 included age and sex.

6
7 Covariates in model 2 included age, sex, occupation, type of health insurance, type of admission, intensive care unit stay, presence of
8
9 CHD, stroke, hypertension, diabetes, COPD, and cancer (except for the disease used to define the subgroup).

10
11 Covariates in model 3 included covariates in model 2, plus the presence of sepsis and pneumonia.

12
13
14 Abbreviations: CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive
15
16 pulmonary disease.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 3. Effects of chronic kidney disease on length of stay, costs, and in-hospital mortality, compared with other major non-communicable diseases

Condition	Covariates in the model	Length of stay % change (95% CI)	Costs % change (95% CI)	In-hospital mortality relative risk (95% CI)
CKD	Model 1	22.34 (22.14, 22.55)	6.49 (6.25, 6.73)	2.31 (2.27, 2.35)
	Model 2	22.09 (21.87, 22.32)	6.82 (6.56, 7.08)	2.23 (2.19, 2.28)
CHD	Model 1	-5.19 (-5.31, -5.07)	27.72 (27.51, 27.94)	1.36 (1.34, 1.38)
	Model 2	-7.31 (-7.44, -7.18)	30.95 (30.71, 31.19)	1.31 (1.29, 1.33)
Stroke	Model 1	16.12 (15.97, 16.27)	9.29 (9.10, 9.48)	1.58 (1.56, 1.60)
	Model 2	17.34 (17.17, 17.51)	9.90 (9.69, 10.11)	1.70 (1.67, 1.73)
Hypertension	Model 1	5.49 (5.39, 5.59)	8.90 (8.77, 9.04)	1.93 (0.92, 0.94)
	Model 2	1.81 (1.69, 1.92)	4.85 (4.70, 5.01)	1.76 (0.75, 0.77)
Diabetes	Model 1	11.36 (11.22, 11.51)	5.05 (4.87, 5.23)	1.13 (1.11, 1.15)
	Model 2	8.96 (8.80, 9.12)	1.00 (0.81, 1.20)	1.99 (0.97, 1.01)
COPD	Model 1	3.89 (3.65, 4.14)	-9.00 (-9.29, -8.71)	1.31 (1.28, 1.34)
	Model 2	5.77 (5.50, 6.04)	-8.67 (-8.98, -8.36)	1.24 (1.21, 1.27)
Cancer	Model 1	8.90 (8.80, 9.00)	27.40 (27.25, 27.55)	2.00 (1.97, 2.02)
	Model 2	13.90 (13.79, 14.02)	39.47 (39.29, 39.65)	2.87 (2.83, 2.91)

Note: Numbers in the table are percent-changes/relative risks of patient records with corresponding disease compared with patient records without corresponding disease.

1
2
3
4
5 Covariates in model 1 included age and sex.

6
7 Covariates in model 2 included age, sex, occupation, type of health insurance, type of admission, intensive care unit stay, presence of
8
9 CKD, CHD, stroke, hypertension, diabetes, COPD, and cancer, and presence of sepsis and pneumonia.

10
11 Abbreviations: CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive
12
13 pulmonary disease.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47




Figure 1. Percentages of coronary angiography and percutaneous coronary intervention for hospitalizations with coronary heart disease

Note: The number of hospitalizations with or without CKD was 3,116 and 68,616 for STEMI, 2,645 and 25,057 for NSTEMI, 124,388 and 1,519,864 for NACS, respectively. For 18,315 hospitalizations with diagnoses of CKD staging, 15.8%, 24.6%, 16.8%, and 42.9% of them were in stage 1-2, 3, 4 and 5.

Abbreviations: CKD, chronic kidney disease; NACS, non-acute coronary syndrome; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.

227x170mm (600 x 600 DPI)

Appendix 1. The International Classification of Diseases-10 coding of chronic kidney disease and other major non-communicable chronic diseases

Disease	ICD-10 coding
CKD	E10.2+, E11.2+, E13.2+, E14.2+, I12.0, I12.9, I13.0, I13.1, I13.2, I13.9, N11, N12, N14, N15, N16.* , E74.8, E72.0, N25.1, M32.1+N08.5* , M32.1+N16.4* , M35.0+N16.4* , M31.0+N08.5* , M31.7+N08.5* , M31.001 [†] , M31.802 [†] , M31.101+N08.5* [†] , M31.102+N08.5* [†] , M31.303+N08.5* [†] , N18, N19, N13.0, N13.1, N13.2, C64, N07, N08 (excluding N08.5*), N13.6, Q60, Q61.1, Q61.2, Q61.3, Q61.5, Q63.1, Q63.9, M10.3, N26, N28.0, N28.8, N28.9, A52.7+N08.0* , N99.0, P96.0, R39.2, K76.7, Q27.1, I70.1, M31.4 (combined with I15.0) N00.8, N02, N03, N04, N05, N06, N39.1
CHD [†]	I21.001, I21.002, I21.004, I21.101, I21.103, I21.104, I21.105, I21.201, I21.202, I21.203, I21.204, I21.205, I21.206, I21.207, I21.208, I21.209, I21.210, I21.211, I21.213, I21.214, I21.215, I21.301, I21.302, I21.304, I21.907, I21.403, I24.003, I20.001, I20.002, I20.003, I20.004, I20.005, I20.006, I20.101, I20.102, I20.802, I20.803, I21.303, I21.401, I21.402, I21.901, I21.902, I21.910, I22.001, I22.101, I22.801, I22.802, I22.803, I22.901, I23.001, I23.002, I23.101, I23.201, I23.301, I24.001, I24.002, I24.003, I24.004, I24.005, I24.006, I24.101, I24.102, I24.801, I24.802, I24.901, I20.801, I20.804, I20.805, I20.806, I20.902, I25.103, I25.104, I25.105, I25.201, I25.202, I25.203, I25.204, I25.205, I25.206, I25.207, I25.208, I25.209, I25.210, I25.211, I25.212, I25.213, I25.214, I25.215, I25.501, I25.601, I25.901, I25.902
CHD [†]	I21.000, I21.001, I21.002, I21.003, I21.004, I21.005, I21.006, I21.007, I21.100, I21.101, I21.102, I21.103, I21.104, I21.105, I21.200, I21.201, I21.202, I21.203, I21.204, I21.205, I21.206, I21.300, I21.301, I21.401, I20.000, I20.001, I20.002, I20.003, I20.004, I20.005, I20.006, I20.100, I20.101, I20.102, I20.804, I21.302, I21.303, I21.400, I21.402, I21.900, I22.000, I22.100, I22.800, I22.900, I23.000, I23.100, I23.200, I23.300, I23.400, I23.500, I23.600, I23.601, I23.800, I24.000, I24.001, I24.100, I24.801, I24.801, I24.801, I24.900, I24.901, I20.801, I20.802, I20.803, I20.804, I20.900, I25.000, I25.100, I25.101, I25.102, I25.103, I25.100, I25.500, I25.600, I25.800, I25.801, I25.900, I25.901,
COPD	J44.901 [†] , J44.003 [†] , J44.103 [†] , J44.900 [†] , J44.000 [†] , J44.100 [†] , J44.800 [†]
Stroke	I60, I61, I63, I64, G45, H34.1
Diabetes	E10, E11, E12, E13, E14
Cancer	C00-C26, C30-C34, C37-C41, C43-C58, C60-C85, C88, C90-C97, D00-D07, D09, D37-D48, B21, Z85, Z88, Z51.10 [†] , Z51.20 [†] , Z51.50 [†] , Z03.101 [†] , E87.805 [†] , O99.8011 [†] , O99.8021 [†] , O99.8024 [†] , O99.8031 [†] , Z51.00 [†] , Z51.10 [†] , Z51.80 [†] , Z03.10 [†] , O99.802 [†] , Z35.802 [†] , Z54.001 [†] , E88.805 [†] , Z86.000 [†]
Hypertension	I10

Disease	ICD-10 coding
Sepsis	A41
Pneumonia	J12-J18

¹Applicable for ICD-10 (Beijing Version 4.0) only.

²Applicable for ICD-10 (National Standard Version1.0) only.

³Denotes to any possible number so that the whole sequence represents all the subclasses of the disease.

Abbreviations: CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary diseases. ICD-10, International Classification of Diseases-10.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Appendix 2. Effects of chronic kidney disease stages 3-5 on length of stay, costs, and in-hospital mortality for each non-communicable disease

Condition	Covariates in the model	Length of stay % change (95% CI)	Costs % change (95% CI)	In-hospital mortality relative risk (95% CI)
CHD	Model 1	36.67 (35.19, 38.17)	14.54 (12.64, 16.47)	1.90 (1.73, 2.08)
	Model 2	38.68 (37.07, 40.30)	6.22 (4.35, 8.13)	1.93 (1.76, 2.13)
	Model 3	38.41 (36.81, 40.03)	5.69 (3.83, 7.58)	1.93 (1.76, 2.13)
Stroke	Model 1	22.81 (20.89, 24.75)	30.39 (27.46, 33.38)	1.12 (1.88, 2.39)
	Model 2	21.76 (19.67, 23.88)	25.48 (22.49, 28.55)	1.92 (1.69, 2.19)
	Model 3	21.13 (19.05, 23.24)	23.60 (20.66, 26.60)	1.79 (1.58, 2.05)
Hypertension	Model 1	19.77 (19.01, 20.54)	0.62 (-0.29, 1.53)	1.60 (1.49, 1.72)
	Model 2	25.88 (25.02, 26.75)	4.10 (3.10, 5.11)	1.83 (1.69, 1.98)
	Model 3	25.69 (24.83, 26.55)	3.47 (2.48, 4.47)	1.76 (1.63, 1.91)
Diabetes	Model 1	23.75 (22.71, 24.80)	10.24 (8.92, 11.58)	1.91 (1.75, 2.09)
	Model 2	29.22 (28.06, 30.40)	13.22 (11.80, 14.65)	2.14 (1.95, 2.36)
	Model 3	29.06 (27.90, 30.23)	12.55 (11.15, 13.98)	2.13 (1.93, 2.34)
COPD	Model 1	14.97 (11.79, 18.25)	36.41 (31.07, 41.97)	1.70 (1.37, 2.12)
	Model 2	15.21 (11.75, 18.77)	22.93 (17.93, 28.14)	1.74 (1.38, 2.19)
	Model 3	15.38 (11.92, 18.95)	22.80 (17.83, 27.97)	1.72 (1.36, 2.16)
Cancer	Model 1	24.54 (21.36, 27.80)	20.65 (17.08, 24.34)	1.15 (1.86, 2.49)
	Model 2	20.58 (17.23, 24.02)	12.13 (8.53, 15.85)	1.68 (1.44, 1.95)
	Model 3	19.72 (16.40, 23.14)	11.26 (7.70, 14.94)	1.49 (1.28, 1.73)

Note: Numbers in the table are percent-changes/relative risks of patient records with CKD compared with patient records without CKD

1
2
3
4
5 for each non-communicable disease. Covariates in model 1 included age and sex.

6
7 Covariates in model 2 included age, sex, occupation, type of health insurance, type of admission, intensive care unit stay, presence of
8
9 CHD, stroke, hypertension, diabetes, COPD, and cancer (except for the disease used to define the subgroup).

10
11 Covariates in model 3 included covariates in model 2, plus the presence of sepsis and pneumonia.

12
13
14 Abbreviations: CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive
15
16 pulmonary disease.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Appendix 3. Effects of chronic kidney disease stages 3-5 on length of stay, costs, and in-hospital mortality, compared with other major non-communicable diseases

Condition	Covariates in the model	Length of stay % change (95% CI)	Costs % change (95% CI)	In-hospital mortality relative risk (95% CI)
CKD	Model 1	32.02 (31.40, 32.65)	14.97 (14.26, 15.70)	1.76 (1.67, 1.85)
	Model 2	35.61 (34.93, 36.30)	19.65 (18.86, 20.45)	1.92 (1.82, 2.02)
CHD	Model 1	-5.95 (-6.08, -5.83)	28.00 (27.78, 28.22)	1.34 (1.32, 1.36)
	Model 2	-7.67 (-7.80, -7.53)	31.31 (31.06, 31.56)	1.32 (1.29, 1.34)
Stroke	Model 1	16.71 (16.55, 16.86)	9.00 (8.81, 9.20)	1.62 (1.60, 1.65)
	Model 2	17.76 (17.59, 17.94)	9.58 (9.37, 9.80)	1.74 (1.71, 1.77)
Hypertension	Model 1	5.07 (4.97, 5.18)	9.26 (9.11, 9.40)	0.92 (0.91, 0.93)
	Model 2	2.15 (2.03, 2.26)	5.11 (4.95, 5.27)	0.78 (0.76, 0.79)
Diabetes	Model 1	10.38 (10.23, 10.53)	5.90 (5.70, 6.10)	1.09 (1.07, 1.11)
	Model 2	9.54 (9.37, 9.71)	1.90 (1.69, 2.11)	1.03 (1.01, 1.05)
COPD	Model 1	3.99 (3.74, 4.24)	-9.96 (-10.25, -9.67)	1.32 (1.29, 1.35)
	Model 2	5.83 (5.56, 6.11)	-9.48 (-9.80, -9.17)	1.24 (1.21, 1.27)
Cancer	Model 1	9.51 (9.41, 9.60)	26.96 (26.80, 27.11)	2.00 (1.98, 2.03)
	Model 2	14.07 (13.95, 14.18)	38.95 (38.76, 39.13)	2.87 (2.82, 2.91)

Note: Numbers in the table are percent-changes/relative risks of patient records with corresponding disease compared with patient records without

1
2
3
4
5 corresponding disease.
6

7
8 Covariates in model 1 included age and sex.
9

10 Covariates in model 2 included age, sex, occupation, type of health insurance, type of admission, intensive care unit stay, presence of CKD, CHD,
11 stroke, hypertension, diabetes, COPD, and cancer, and presence of sepsis and pneumonia.
12
13

14
15 Abbreviations: CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6-7
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-10
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	-
		(d) If applicable, describe analytical methods taking account of sampling strategy	10
		(e) Describe any sensitivity analyses	-
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11
		(b) Indicate number of participants with missing data for each variable of interest	-
Outcome data	15*	Report numbers of outcome events or summary measures	11-13

BMJ Open

Healthcare resource utilization of chronic kidney disease and other major non-communicable chronic diseases in China: a cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-051888.R2
Article Type:	Original research
Date Submitted by the Author:	23-Nov-2021
Complete List of Authors:	Yang, Chao; Peking University First Hospital, Long, Jianyan; First Affiliated Hospital of Sun Yat-Sen University, Clinical Trial Unit Shi, Ying; China Standard Medical Information Research Center Zhou, Zhiye; China Standard Medical Information Research Center Wang, Jinwei; Peking University First Hospital Zhao, Ming-Hui; Peking University Institute of Nephrology, Renal Division Wang, Haibo; First Affiliated Hospital of Sun Yat-Sen University; National Institute of Health Data Science at Peking University Zhang, Luxia; Peking University First Hospital; National Institute of Health Data Science at Peking University Coresh, J; Johns Hopkins University Bloomberg School of Public Health, Department of Epidemiology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Epidemiology, Renal medicine, Public health, Cardiovascular medicine, Diabetes and endocrinology
Keywords:	Public health < INFECTIOUS DISEASES, Epidemiology < TROPICAL MEDICINE, Chronic renal failure < NEPHROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Healthcare resource utilization of chronic kidney disease and other**
4 **major non-communicable chronic diseases in China: a cross-sectional**
5 **study**
6
7
8
9

10 Running head: CKD and NCDs in China
11
12
13

14
15
16 Chao Yang, MS^{1,2,7}; Jianyan Long, MSc³; Ying Shi, BMS⁴; Zhiye Zhou, MSc⁴; Jinwei
17 Wang, PhD^{1,2}; Ming-Hui Zhao, MD^{1,2,5}; Haibo Wang, MBBS, MSc, MPH^{3,6,*}; Luxia
18 Zhang, MD, MPH^{1,6,7,*}; Josef Coresh, MD, PhD⁸
19
20
21
22

23
24
25 ¹*Renal Division, Department of Medicine, Peking University First Hospital, Peking*
26 *University Institute of Nephrology, Beijing, China*
27

28
29 ²*Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases,*
30 *Chinese Academy of Medical Sciences, Beijing, China*
31

32
33 ³*Clinical Trial Unit, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,*
34 *Guangdong, China*
35

36
37 ⁴*China Standard Medical Information Research Center, Shenzhen, Guangdong, China*
38

39
40 ⁵*Peking-Tsinghua Center for Life Sciences, Beijing, China*
41

42
43 ⁶*National Institute of Health Data Science at Peking University, Beijing, China*
44

45
46 ⁷*Advanced Institute of Information Technology, Peking University, Hangzhou, Zhejiang,*
47 *China*
48

49
50 ⁸*Department of Epidemiology, Johns Hopkins University Bloomberg School of Public*
51 *Health, Baltimore, MD, USA*
52
53
54

1
2
3 ***Corresponding authors:** Luxia Zhang, MD, MPH, Renal Division, Department of
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Medicine, Peking University First Hospital, Peking University Institute of Nephrology,
No. 8, Xishiku Street, Xicheng District, Beijing 100034, China. Phone: +86-10-8357-
5817, Fax: +86-10-6655-1055, E-mail: zhanglx@bjmu.edu.cn; Haibo Wang, MBBS,
MSc, MPH, Clinical Trial Unit, First Affiliated Hospital of Sun Yat-Sen University,
Guangzhou 510080, China; Phone: +86-755-3331-9080, Fax: +86-755-3331-9061, E-
mail: haibo@mail.harvard.edu.

Abstract

Objective: To evaluate the healthcare resource utilization of chronic kidney disease (CKD) and other major non-communicable chronic diseases (NCDs) in China.

Design: A cross-sectional study.

Setting: A national inpatient database of tertiary hospitals in China.

Participants: A total of 19.5 million hospitalizations of adult patients from July, 2013 to June, 2014. Information on CKD and other major NCDs, including coronary heart disease (CHD), stroke, hypertension, diabetes, chronic obstructive pulmonary disease (COPD), and cancer was extracted from the unified discharge summary form.

Outcome measures: Costs, length of hospital stay, and in-hospital mortality.

Results: The percentages of hospitalizations with CKD, CHD, stroke, hypertension, diabetes, COPD, and cancer were 4.5%, 9.2%, 8.2%, 18.8%, 7.9%, 2.3%, and 19.4%, respectively. For each major NCD, the presence of CKD was independently associated with longer hospital stay, with increased percentages ranging from 7.69% (95% confidence interval [CI], 7.11%–8.28%) for stroke to 21.60% (95% CI, 21.09%–22.10%) for CHD. The hospital mortality for other NCDs was also higher in the presence of CKD, with fully adjusted relative risk ranging from 1.91 (95% CI, 1.82–1.99) for stroke to 2.65 (95% CI, 2.55–2.75) for cancer. Compared with other NCDs, CKD was associated with the longest hospital stay (22.1% increase) and resulted in the second highest in-hospital mortality, only lower than that of cancer (relative risk, 2.23 vs. 2.87, respectively).

Conclusions: The presence of diagnosed CKD alongside each major NCD was associated with an additional burden on the healthcare system. The healthcare resource utilization and prognosis of CKD were comparable to those of other major NCDs, which

1
2
3 highlights the importance of CKD as a major public health burden.
4
5
6

7
8 **Keywords**
9

10 Chronic kidney disease; Disease burden; Health care costs; Length of stay; Mortality;
11

12 Non-communicable chronic disease
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

- The first national study placing the CKD burden on hospital stay and mortality in the full context of all major NCDs.
- Large sample size and wide geographical coverage.
- Only tertiary hospitals were included, which might have led to population selection bias.
- Diagnosis of major NCDs was based on the ICD-10 coding with low sensitivity.
- Data of eGFR or proteinuria and information on medications were not available.

Background

There is a rising burden of non-communicable diseases (NCDs) at a global level. Two of three deaths each year are attributable to NCDs, and four-fifths of NCD-related deaths occur in low- and middle-income countries.¹ This exerts a significant influence on the healthcare system and costs worldwide.² Taking action against NCDs is, therefore, an economic imperative.³ The priority actions for the NCD crisis were released by the United Nations High-Level Meeting in 2011, focusing on the prevention and control of heart disease, stroke, cancer, diabetes, and chronic respiratory diseases.¹ The world leaders also committed to reduce premature deaths from NCDs by one-third by 2030.³

Over the past decade, chronic kidney disease (CKD) has been recognized as a major public health issue worldwide, with an estimated prevalence of more than 10%.^{4,5} By 2040, CKD is estimated to become the fifth leading cause of early death globally—one of the largest projected increases of any major cause of death.⁶ In China, CKD is prevalent and is associated with more severe comorbidities and higher medical expenditures.^{7,8} However, unlike other NCDs, such as diabetes, the awareness of CKD is low among patients and healthcare providers.⁹ Besides, CKD is a key determinant of poor health outcomes of major NCDs and a risk multiplier in patients with cardiovascular disease (CVD), diabetes, and hypertension.¹⁰ Due to the fact that the kidneys are usually target organs of systemic vascular, hemodynamic, metabolic, and inflammatory disorders, the pandemic of NCDs also leads to a persistently increasing morbidity of CKD.¹¹ There is accumulating evidence that major NCDs, including heart disease and stroke, have a poor prognosis in the presence of CKD.¹²⁻¹⁴ Moreover, CKD has been reported to be associated with reduced implementation of best clinical practice, which could lead to suboptimal

1
2
3 treatment and adverse outcomes, especially for patients with CVD.¹⁵
4

5 Although CKD is a global health issue, to the best of our knowledge, there have
6 been neither large-scale studies to quantitatively evaluate the burden of CKD on all major
7 NCDs, nor studies comparing the burden of CKD with other NCDs. The evidence for the
8 healthcare resource utilization associated with CKD and other major NCDs at a national
9 level is limited, which impedes the development of effective preventive strategies. In
10 addition, little is known about the status of cardiac procedures for patients with CKD in
11 China. Hence, we initiated this observational study to comprehensively and quantitatively
12 evaluate the healthcare resource utilization and prognosis of CKD and other NCDs, as
13 well as to compare the burden of kidney diseases on the healthcare system with other
14 NCDs among hospitalized patients in China.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Methods**

31 *Study population*

32
33 The Hospital Quality Monitoring System (HQMS) is a mandatory patient-level national
34 database for hospital accreditation under the authority of the National Health
35 Commission of the People's Republic of China. Details of HQMS have been described
36 elsewhere.^{16 17} In brief, all tertiary hospitals in China have been requested to submit
37 electronic inpatient discharge records to the HQMS on a daily basis. Unlike the Western
38 medical system, tertiary hospitals in China provide primary, secondary, and tertiary care
39 and have exposure to a nationwide patient population. Patient-level data were collected
40 from uniform front pages of hospitalization medical records. Altogether 353 variables
41 including demographic characteristics, clinical diagnoses, procedures, pathology
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 diagnoses, and expenditure breakdowns were collected. All personal information has
4 already been de-identified to protect the patient privacy. The diagnoses were coded based
5 on the International Classification of Diseases-10 (ICD-10) coding system by certified
6 professional medical coders at every hospital. As the part of stringent standard practice in
7 China, the inpatient discharge records have the legal validity and must be filed by the
8 care-giving doctors who have the most accurate and comprehensive understanding of the
9 patient's medical condition.

10
11
12
13
14
15
16
17
18
19 A total of 19,518,990 records of adult inpatients admitted from July 1, 2013 to June
20 30, 2014 in 29 provinces (excluding Hong Kong, Macao, Taiwan, Tibet, and Ningxia)
21 were included in this cross-sectional study, with certain patients having more than one
22 hospitalization. During this period, 715 tertiary hospitals in China, accounting for 44% of
23 all tertiary hospitals in the country, had submitted inpatient records to the HQMS
24 database. Hospitalizations were used in the present analysis since they are more relevant
25 to the discussion of "disease burden".¹⁸ This study was approved by the Ethics
26 Committee of Peking University First Hospital (2015-928) and informed consent was
27 waived by the Ethics Committee.

41 42 *Definition of CKD*

43
44 The ICD-10 coding of discharge diagnoses was used to identify patients with CKD.^{16 17}
45 Hospitalizations of patients with at least one of the following diagnoses (in both primary
46 diagnosis and secondary diagnoses) were identified as having CKD (relevant ICD-10
47 coding in supplemental Appendix 1): glomerulonephritis, diabetic nephropathy,
48 hypertensive nephropathy, obstructive nephropathy, renal cancer, tubulointerstitial

1
2
3 nephritis, kidney disease secondary to autoimmune diseases, kidney failure of unknown
4
5 reason. Among patients' records with CKD, only 14% of them had the information on
6
7 CKD staging.
8
9

10 11 12 13 14 *Validation study*

15
16
17
18 Since the laboratory results are not included in the HQMS dataset, we performed a
19
20 validation study using 67,376 hospitalizations in three hospitals in the HQMS. Those
21
22 were the pilot hospitals that accomplished the HQMS phase 2 data collection expansion
23
24 to the data of laboratory tests and medications.¹⁹ The estimated glomerular filtration rate
25
26 (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) Study
27
28 equation tailored for Chinese CKD patients.²⁰ Proteinuria was defined by urinary
29
30 albumin-to-creatinine ratio (ACR) ≥ 30 mg/g creatinine, and/or urinary protein \geq trace in
31
32 the urine routine test. CKD was defined as the presence of proteinuria and/or eGFR less
33
34 than 60 ml/min/1.73 m². Compared with the gold standard, the sensitivity and specificity
35
36 of CKD identification by ICD-10 coding was 34.2% and 97.8%, respectively.¹⁹
37
38
39
40
41
42
43

44 *Definition of other NCDs*

45
46 Major NCDs, including coronary heart disease (CHD), stroke, hypertension, diabetes,
47
48 chronic obstructive pulmonary disease (COPD), and cancer,¹ were identified by the ICD-
49
50 10 coding of hospital discharge diagnoses (in both primary and secondary diagnoses,
51
52 relevant ICD-10 coding in supplemental Appendix 1). Information on coronary
53
54 angiography (CAG), percutaneous coronary intervention (PCI), and coronary artery
55
56
57
58
59
60

bypass grafting was obtained from the procedure coding of the inpatient discharge records for patients with CHD. For patients with multiple NCD diagnoses, each relevant diagnosis was identified and counted when stratified by the above NCDs.

Other covariates

Individual variables including age, sex, occupation (professional, worker, farmer, retired, unemployed, and others), type of health insurance (basic medical insurance, new rural cooperative medical care, other types of insurance, and uninsured), type of admission (emergency, routine, and others), and intensive care unit (ICU) stay were collected from the HQMS database.

Outcomes

Hospitalization costs and length of hospital stay, which are both important indicators for healthcare resource utilization, were acquired from the clinical charts in electronic inpatient discharge records. The total costs of the patient's hospitalization were jointly borne by the patient, the government, and related insurers, and included costs for prescribed drugs, hospital beds, laboratory tests, medical examinations, and surgical costs. The total cost information was summarized and reported by each hospital, and we extracted it directly from the HQMS database. Information on in-hospital mortality was also collected to assess the prognosis of patients. The survival status of each patient was verified based on the discharge status and combined with the information of autopsy.

Statistical analysis

1
2
3 General characteristics stratified by the presence of CKD for each NCD were described.
4
5 Continuous data were presented as mean \pm standard deviation, or as median (interquartile
6
7 range) for highly skewed variables. Categorical variables were presented as proportions.
8
9
10 All of the analyses were based on the hospitalizations (patient records), not individuals.
11

12 The effects of CKD on the healthcare resource utilization for each NCD were
13
14 analyzed using generalized regression models for log-transformed cost and length of stay
15
16 with log-link function and gamma distribution. Due to the low mortality and large sample
17
18 size, Poisson regression model was used to evaluate the burden of CKD and other NCDs
19
20 on in-hospital mortality. Percent of change (% change) and relative risk (RR) with 95%
21
22 confidence interval (CI) were calculated as $\exp(\beta)-1$ from the generalized regression
23
24 model and $\exp(\beta)$ from the Poisson regression model, respectively. For the purpose of
25
26 assessing additional effects of CKD, covariates included in the model for the sub-dataset
27
28 of each NCD were age (5-year categories, except for 18–25 years and >80 years), sex
29
30 (male vs. female), type of health insurance (dummy variable), type of admission (dummy
31
32 variable), ICU stay (yes vs. no), presence of CKD (yes vs. no), presence of other NCDs
33
34 (yes vs. no), pneumonia (yes vs. no), and sepsis (yes vs. no).
35
36
37
38
39

40 Then, the presence of CKD and other NCDs was included in the models
41
42 simultaneously, using the data of all hospitalized patients, in order to compare the effect
43
44 of CKD with that of other NCDs on outcome variables. Similar covariates were used as
45
46 described previously.
47
48

49 For hospitalized patients with CHD, the percentages of those with CAG and PCI
50
51 were reported among different clinical types (including ST-segment elevation myocardial
52
53 infarction, non-ST-segment elevation myocardial infarction, and non-acute coronary
54
55
56
57
58
59

1
2
3 syndrome), stratified by the presence of CKD. Among 18,315 hospitalizations with CHD
4 and with available CKD staging, the percentages of those with CAG and PCI were also
5 reported.
6
7
8

9
10 The sensitivity analysis was conducted among patients with CKD stages 3-5 to
11 further determine the healthcare resource utilization of CKD (Appendices 2 and 3). All
12 analyses were performed using the SAS software, version 9.4 (SAS Institute Inc, Cary,
13 NC). Due to the large sample size of our study, *P* values were not reported for between-
14 group comparisons.
15
16
17
18
19
20
21
22
23

24 *Patient and public involvement statement*

25
26 Patients or the public were not involved in this study.
27
28
29
30

31 **Results**

32
33 Among 19.5 million hospitalizations, the percentages of diagnosed CKD, CHD, stroke,
34 hypertension, diabetes, COPD, and cancer were 4.5%, 9.2%, 8.2%, 18.8%, 7.9%, 2.3%,
35 and 19.4%, respectively (table 1). For each major NCD, individuals with CKD were older
36 (except for hypertension); were more often male and urban residents; more often stayed
37 in ICU and had infectious diseases such as pneumonia and sepsis (except for COPD).
38
39
40
41
42
43

44
45 For each major NCD, the presence of CKD was independently associated with
46 longer hospital stay, with increased percentages ranging from 7.69% (95% CI, 7.11%–
47 8.28%, for stroke) to 21.60% (95% CI, 21.09%–22.10%, for CHD) (Table 2). After
48 adjusting for potential confounders, the presence of CKD was associated with higher
49 costs for stroke (11.15%; 95% CI, 10.31%–11.99%), COPD (19.46%; 95% CI, 17.97%–
50
51
52
53
54
55
56
57
58
59
60

20.97%), and cancer (18.88%; 95% CI, 17.98%–19.78%). In contrast, the costs were slightly lower for CHD (acute coronary syndrome or non-acute coronary syndrome) (–1.08%; 95% CI, –1.71% to –0.45%), hypertension (–0.22%; 95% CI, –0.60% to 0.16%), and diabetes (–0.97%; 95% CI, –1.43% to –0.51%) in the presence of CKD (Table 2). If patients with CHD were excluded, the presence of CKD was associated with increased costs for patients with hypertension and diabetes, with a fully adjusted change of 2.70% (95% CI, 2.24%–3.15%) and 4.11% (95% CI, 3.56%–4.66%), respectively. The in-hospital mortality was also higher in the presence of CKD for major NCDs, with fully adjusted RR ranging from 1.91 (95% CI, 1.82–1.99, for stroke; 95% CI, 1.85–1.97, for hypertension) to 2.65 (95% CI, 2.55–2.75, for cancer) (Table 2).

Among hospitalizations with CHD, the percentages of individuals with CAG and PCI were substantially lower for those with CKD (Figure 1). A similar pattern was observed for coronary artery bypass grafting, which was 0.3% and 1.0% for CHD patients with or without CKD, respectively. Even for those with acute coronary syndrome or cardiogenic shock—a strong indication for emergency PCI²¹—the trend was still similar: 11.9% vs. 22.2% for ST-elevated myocardial infarction, and 3.5% vs. 7.3% for non-ST elevated myocardial infarction. Furthermore, among hospitalizations with available CKD staging and with CHD, the percentages of individuals with CAG and PCI were lower even for stage 1 and 2, compared with those without CKD and with CHD (Figure 1).

Compared with other NCDs, CKD had the highest increase in length of hospital stay (22.09%; 95% CI, 21.87%–22.32%) (Table 3). Cancer and CHD were associated with the highest contribution to increased costs for hospitalized patients, which was 39.47% (95%

1
2
3 CI, 39.29%–39.65%) and 30.95% (95% CI, 30.71%–31.19%), respectively. CKD was
4 associated with 6.82% (95% CI, 6.56%–7.08%) increased costs. Furthermore, CKD
5 resulted in the second highest in-hospital mortality (RR, 2.23; 95% CI, 2.19–2.28), which
6 was only lower than that of cancer (RR, 2.87; 95% CI, 2.83–2.91).
7
8
9
10
11
12
13

14 Discussion

15
16 This study is the first national quantitative study on the burden of CKD and other major
17 NCDs on the healthcare system in China. The findings of this study indicated that the
18 presence of CKD was associated with additional burden on the healthcare system and
19 increased in-hospital mortality for each major NCD, despite evidence of under-utilization
20 of cardiac procedures in the presence of CKD. Furthermore, the healthcare resource
21 utilization of CKD was comparable to those of other major NCDs in this large national
22 sample of 19.5 million hospitalizations.
23
24
25
26
27
28
29
30
31
32

33 Studies regarding the utilization of healthcare resources for CKD mostly focused on
34 end-stage kidney disease (ESKD).^{22–24} The US Renal Data System 2019 Annual Data
35 Report showed that the costs for both CKD and ESKD were in excess of \$120 billion in
36 2017, and the latter accounted for more than 7.2% of the total Medicare expenditure.²⁵
37 Our study revealed that CKD was associated with a 6.8% increase in costs, which was
38 higher than that of hypertension, diabetes, and COPD. Moreover, for each major NCD,
39 the presence of CKD led to longer hospital stay, which is also an important marker for
40 the healthcare resource utilization. Furthermore, considering the evidence of therapeutic
41 nihilism for patients with CKD (documented for cardiac revascularization) and the
42 insensitivity of diagnostic codes for CKD, the burden of CKD on the healthcare system
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 might be underestimated. A recent systematic review has also shown that the risks of
4
5 adverse cardiovascular outcomes increase with CKD and are associated with substantial
6
7 additional costs and resource utilization.²⁶
8
9

10 Several previous studies have reported that both the general and high-risk
11
12 populations have poor prognoses in the presence of kidney diseases. For example, using
13
14 the data of 1.1 million adults within a large integrated healthcare system, Go *et al.*
15
16 observed increased risks of all-cause mortality, CVD, and hospitalization associated with
17
18 reduced kidney function.¹² A recent meta-analysis has reported that both reduced eGFR
19
20 and elevated urinary albumin-to-creatinine ratio are associated with increased all-cause
21
22 and cardiovascular mortality in the general population.²⁷ Similarly, using data from over
23
24 40 cohorts involving one million participants, it has been reported that the adjusted
25
26 hazard ratio for all-cause mortality at an eGFR of 45 ml/min/1.73 m² was 1.24 (95% CI,
27
28 1.11–1.39) for those with hypertension,²⁸ and was 1.35 (95% CI 1.18–1.55) for those with
29
30 diabetes,²⁹ compared with those with eGFR of 95 ml/min/1.73 m². In this study, we
31
32 further expanded the observation to a range of other major NCDs, including CHD, stroke,
33
34 COPD, and cancer. We found that CKD was consistently associated with the increased
35
36 in-hospital mortality for each major NCD, and its impact was higher compared with that
37
38 of the majority of NCDs, even comparable to that of cancer. These findings further
39
40 highlight the importance of CKD as a major health burden and are consistent with the
41
42 implications of Global Burden of Disease, Injuries, and Risk Factors Study, which has
43
44 shown the high burden and rapid growth of CKD as a direct cause of morbidity and
45
46 mortality.^{4 6}
47
48
49
50
51
52

53 The potential mechanisms for the association of CKD and adverse outcomes are
54
55
56
57
58
59
60

1
2
3 complex and not fully understood. A previous study indicated that impaired kidney
4 function could lead to multiple adverse systemic alterations, including inappropriate
5 activation of the renin-angiotensin system, catalytic iron-dependent oxidative stress,
6 endothelial dysfunction, and inflammation.¹⁴ In addition, for patients whose CKD is a
7 result of a systemic disease such as diabetes, kidney diseases might only serve as a
8 marker of the severity of the target organ damage.
9

10
11
12 Another explanation for the adverse outcomes observed in patients with CKD might
13 be that the presence of CKD is associated with the reduced implementation of best
14 practice. Although the accumulating evidence and the Kidney Disease: Improving Global
15 Outcomes (KDIGO) guidelines with international consensus suggest that the level of care
16 for ischemic heart disease offered to patients with CKD should not be prejudiced by their
17 CKD,³⁰ our data on revascularization indicate that the cardiac treatment for patients with
18 CKD is suboptimal. Under-utilization of aspirin, beta-blockers, angiotensin-converting
19 enzyme inhibitors, glycoprotein IIb/IIIa receptor antagonists, and thrombolytic therapy
20 has been observed in CKD patients due to concerns of bleeding risk, worsening of kidney
21 function, and comorbidities.¹⁵ A recent study from the United States indicated that,
22 compared with those without CKD, patients with CKD reported more medication use for
23 cardiovascular risk factors but had poorer risk factor control.³¹ In our study, the
24 percentages of hospitalizations with CAG and PCI were much lower for those with CKD,
25 even for those with relatively well-preserved kidney function, consistent with the practice
26 outside of China.¹⁵ A recent meta-analysis has revealed that for patients with pre-dialysis
27 CKD and with unstable angina or non-ST-segment-elevation myocardial infarction, an
28 early invasive strategy is associated with the risk of re-hospitalization and reduced risk of
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 death and non-fatal re-infarction.³² However, the risk of adverse clinical events after
4 coronary revascularization and the percentage of later additional PCI are also increased in
5 patients with CKD.^{33 34} Hence, a multidisciplinary team involving various subspecialties
6 is needed to improve the quality of care for CKD patients, and appropriate management
7 by primary care clinicians is necessary to prevent CKD-associated adverse outcomes.³⁵
8
9

10 To our knowledge, this is the first study that places the CKD burden on hospital stay
11 and mortality in the full context of all major NCDs in a national database with large
12 sample size and wide geographical coverage, which enables us to analyze the burden of
13 multiple major NCDs simultaneously. However, our study does have some limitations.
14 First, although our data were restricted to hospitalized patients, hospitalization inherently
15 reflects the indication for admission and referral as well as disease burden. Only tertiary
16 hospitals were included in our analyses, which might have led to population selection
17 bias; nevertheless, 715 hospitals in our study covered almost all provinces of China and
18 included all types of tertiary hospitals. Second, the diagnosis of CKD and major NCDs in
19 hospitalized patients was based on the ICD-10 coding, which has the low sensitivity.
20 Severe cases of CKD were likely to be diagnosed, which might affect the extrapolation of
21 the results and lead to a potential overestimation of the excess risk associated with CKD.
22 However, the high specificity of CKD identification (97.8%) is the strength of our study.
23 Third, the low usage of CKD-staging codes was a limitation that should be recognized.
24 Fourth, since hospitalizations were identified using both primary and secondary
25 diagnoses, the direct contribution of specific NCDs to health resource utilization might
26 have been compromised. All of the analyses were based on the hospitalizations, and cases
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 reported in the results were not mutually exclusive, which may also affect the estimations
4
5 of the true burden of disease. Finally, data on eGFR or proteinuria and information on
6
7 medications used and the severity of major NCDs were not available for all patient
8
9 records in our dataset.
10
11
12
13

14 **Conclusions**

15
16 In a systematic national assessment of diagnosed NCDs over 19.5 million hospitalizations
17
18 in China, we showed that the adverse effects of CKD at both individual level and
19
20 healthcare system level were comparable to those of other major NCDs, and the presence
21
22 of CKD was associated with poor prognosis of other NCDs. Therefore, CKD should be
23
24 integrated into the global prevention strategy of NCDs. In consideration of the
25
26 complexity of the disease, a multilevel interdisciplinary approach will be needed to
27
28 address the public health burden of CKD.
29
30
31
32
33
34

35 **Acknowledgments**

36
37 The authors thank the Bureau of Medical Administration and Medical Service
38
39 Supervision, National Health Commission of China for the support of this study.
40
41
42
43

44 **Contributors**

45
46 HW and LZ conceived and coordinated the study and acquired the data. CY, HW, and LZ
47
48 designed the study. CY and LZ searched the literature. CY and JL prepared the figure.
49
50 CY, HW, and LZ wrote the first draft manuscript. CY, JL, SY, and ZZ contributed to the
51
52 analysis. CY, JL, SY, ZZ, JW, M-HZ, HW, LZ, and JC contributed to the interpretation.
53
54
55
56
57
58
59
60

1
2
3 CY, JL, SY, ZZ, JW, M-HZ, HW, LZ, and JC edited the manuscript. All authors
4
5 critically reviewed the manuscript and approved the final version.
6
7
8
9

10 **Funding**

11
12 This study was supported by grants from the National Natural Science Foundation of
13
14 China (82003529, 91846101, 81771938, 81900665, 82090021), Beijing Nova
15
16 Programme Interdisciplinary Cooperation Project (Z191100001119008), National Key
17
18 R&D Program of the Ministry of Science and Technology of China (2019YFC2005000),
19
20 Chinese Scientific and Technical Innovation Project 2030 (2018AAA0102100), the
21
22 University of Michigan Health System-Peking University Health Science Center Joint
23
24 Institute for Translational and Clinical Research (BMU2018JI012, BMU2019JI005,
25
26 71017Y2027), CAMS Innovation Fund for Medical Sciences (2019-I2M-5-046), and
27
28 PKU-Baidu Fund (2019BD017, 2020BD032).
29
30
31
32
33
34

35 **Competing interests**

36
37 JC was partly supported by grants to the CKD Prognosis Consortium by the National
38
39 Kidney Foundation and NIH.
40
41
42
43
44

45 **Patient and public involvement statement**

46
47 Patients or the public were not involved in this study.
48
49
50

51 **Patient consent for publication**

52
53 Not required.
54
55
56
57
58
59
60

Ethics approval

Ethical approval was obtained from the Ethics Committee of Peking University First Hospital (2015-928).

Data availability statement

The data that support the findings of this study are available from the Bureau of Medical Administration and Medical Service Supervision, National Health Commission of China but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the Bureau of Medical Administration and Medical Service Supervision, National Health Commission of China.

Supplementary material

Appendix 1. The International Classification of Diseases-10 coding of chronic kidney disease and other major non-communicable chronic diseases

Appendix 2. Effects of chronic kidney disease stages 3-5 on length of stay, costs, and in-hospital mortality for each non-communicable disease

Appendix 3. Effects of chronic kidney disease stages 3-5 on length of stay, costs, and in-hospital mortality, compared with other major non-communicable diseases

ORCID iDs

1
2
3 Chao Yang <https://orcid.org/0000-0001-9682-8395>

4
5 Luxia Zhang <https://orcid.org/0000-0003-2349-2936>

6
7
8
9
10
11
12
13
14
15 **Reference**

- 16
17
18 1. Beaglehole R, Bonita R, Horton R, et al. Priority actions for the non-communicable
19 disease crisis. *Lancet (London, England)* 2011;377(9775):1438-47. doi:
20 10.1016/s0140-6736(11)60393-0 [published Online First: 2011/04/09]
21
22
23 2. Hunter DJ, Reddy KS. Noncommunicable diseases. *The New England journal of*
24 *medicine* 2013;369(14):1336-43. doi: 10.1056/NEJMra1109345 [published
25 Online First: 2013/10/04]
26
27
28 3. Organization WH. Noncommunicable diseases progress monitor 2020, 2020.
29
30
31 4. Collaboration GCKD. Global, regional, and national burden of chronic kidney disease,
32 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
33 *Lancet (London, England)* 2020;395(10225):709-33. doi: 10.1016/S0140-
34 6736(20)30045-3
35
36
37 5. Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from
38 subspecialty to global health burden. *Lancet (London, England)*
39 2013;382(9887):158-69. doi: 10.1016/s0140-6736(13)60439-0 [published Online
40 First: 2013/06/04]
41
42
43 6. Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life
44 lost, and all-cause and cause-specific mortality for 250 causes of death: reference
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 and alternative scenarios for 2016-40 for 195 countries and territories. *Lancet*
4
5 (*London, England*) 2018;392(10159):2052-90. doi: 10.1016/s0140-
6
7 6736(18)31694-5 [published Online First: 2018/10/21]
8
9
- 10 7. Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a
11
12 cross-sectional survey. *Lancet (London, England)* 2012;379(9818):815-22. doi:
13
14 10.1016/s0140-6736(12)60033-6 [published Online First: 2012/03/06]
15
16
- 17 8. Yang C, Gao B, Zhao X, et al. Executive summary for China Kidney Disease Network
18
19 (CK-NET) 2016 Annual Data Report. *Kidney international* 2020;98(6):1419-23.
20
21 doi: 10.1016/j.kint.2020.09.003 [published Online First: 2020/12/06]
22
23
- 24 9. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and
25
26 perspectives. *Lancet (London, England)* 2013;382(9888):260-72. doi:
27
28 10.1016/s0140-6736(13)60687-x [published Online First: 2013/06/04]
29
30
- 31 10. Couser WG, Remuzzi G, Mendis S, et al. The contribution of chronic kidney disease
32
33 to the global burden of major noncommunicable diseases. *Kidney international*
34
35 2011;80(12):1258-70. doi: 10.1038/ki.2011.368 [published Online First:
36
37 2011/10/14]
38
39
- 40 11. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the
41
42 United States. *Jama* 2007;298(17):2038-47. doi: 10.1001/jama.298.17.2038
43
44 [published Online First: 2007/11/08]
45
46
- 47 12. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death,
48
49 cardiovascular events, and hospitalization. *The New England journal of medicine*
50
51 2004;351(13):1296-305. doi: 10.1056/NEJMoa041031 [published Online First:
52
53 2004/09/24]
54
55
56
57
58
59

- 1
2
3 13. Lee M, Saver JL, Chang KH, et al. Low glomerular filtration rate and risk of stroke:
4 meta-analysis. *BMJ (Clinical research ed)* 2010;341:c4249. doi:
5
6 10.1136/bmj.c4249 [published Online First: 2010/10/05]
7
8
9
10 14. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney
11 disease. A clinical update from Kidney Disease: Improving Global Outcomes
12 (KDIGO). *Kidney international* 2011;80(6):572-86. doi: 10.1038/ki.2011.223
13
14 [published Online First: 2011/07/14]
15
16
17
18 15. Cai Q, Mukku VK, Ahmad M. Coronary artery disease in patients with chronic
19 kidney disease: a clinical update. *Current cardiology reviews* 2013;9(4):331-9.
20
21 doi: 10.2174/1573403x10666140214122234 [published Online First: 2014/02/18]
22
23
24
25 16. Zhang L, Long J, Jiang W, et al. Trends in Chronic Kidney Disease in China. *The*
26
27
28
29
30
31
32
33
34 17. Zhang L, Zhao MH, Zuo L, et al. China Kidney Disease Network (CK-NET) 2016
35 Annual Data Report. *Kidney international supplements* 2020;10(2):e97-e185. doi:
36
37
38
39
40
41 18. Hirode G, Saab S, Wong RJ. Trends in the Burden of Chronic Liver Disease Among
42 Hospitalized US Adults. *JAMA network open* 2020;3(4):e201997. doi:
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
19. Huang YM, Xu D, Long J, et al. Spectrum of chronic kidney disease in China: A
national study based on hospitalized patients from 2010 to 2015. *Nephrology*
(*Carlton, Vic*) 2019;24(7):725-36. doi: 10.1111/nep.13489 [published Online First:
2018/09/11]

- 1
2
3 20. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating
4
5 equation for Chinese patients with chronic kidney disease. *Journal of the*
6
7 *American Society of Nephrology* : *JASN* 2006;17(10):2937-44. doi:
8
9 10.1681/asn.2006040368 [published Online First: 2006/09/22]
10
11
12 21. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on
13
14 Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease:
15
16 A Report of the American College of Cardiology/American Heart Association
17
18 Task Force on Clinical Practice Guidelines: An Update of the 2011
19
20 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011
21
22 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012
23
24 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and
25
26 Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA
27
28 Guideline for the Management of ST-Elevation Myocardial Infarction, 2014
29
30 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation
31
32 Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative
33
34 Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac
35
36 Surgery. *Circulation* 2016;134(10):e123-55. doi: 10.1161/cir.0000000000000404
37
38 [published Online First: 2016/03/31]
39
40
41
42
43
44 22. Wong CKH, Chen J, Fung SKS, et al. Direct and indirect costs of end-stage renal
45
46 disease patients in the first and second years after initiation of nocturnal home
47
48 haemodialysis, hospital haemodialysis and peritoneal dialysis. *Nephrology,*
49
50 *dialysis, transplantation* : *official publication of the European Dialysis and*
51
52
53
54
55
56
57
58
59
60

- 1
2
3 *Transplant Association - European Renal Association* 2019;34(9):1565-76. doi:
4
5 10.1093/ndt/gfy395 [published Online First: 2019/01/23]
6
7
8 23. Becker BN, Luo J, Gray KS, et al. Association of Chronic Condition Special Needs
9
10 Plan With Hospitalization and Mortality Among Patients With End-Stage Kidney
11
12 Disease. *JAMA network open* 2020;3(11):e2023663. doi:
13
14 10.1001/jamanetworkopen.2020.23663 [published Online First: 2020/11/03]
15
16
17 24. Wang V, Vilme H, Maciejewski ML, et al. The Economic Burden of Chronic Kidney
18
19 Disease and End-Stage Renal Disease. *Seminars in nephrology* 2016;36(4):319-
20
21 30. doi: 10.1016/j.semnephrol.2016.05.008 [published Online First: 2016/08/01]
22
23
24 25. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 Annual Data
25
26 Report: Epidemiology of Kidney Disease in the United States. *American journal*
27
28 *of kidney diseases : the official journal of the National Kidney Foundation*
29
30 2020;75(1 Suppl 1):A6-a7. doi: 10.1053/j.ajkd.2019.09.003 [published Online
31
32 First: 2019/11/11]
33
34
35 26. Darlington O, Dickerson C, Evans M, et al. Costs and Healthcare Resource Use
36
37 Associated with Risk of Cardiovascular Morbidity in Patients with Chronic
38
39 Kidney Disease: Evidence from a Systematic Literature Review. *Advances in*
40
41 *therapy* 2021 doi: 10.1007/s12325-020-01607-4 [published Online First:
42
43 2021/01/13]
44
45
46
47 27. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular
48
49 filtration rate and albuminuria with all-cause and cardiovascular mortality in
50
51 general population cohorts: a collaborative meta-analysis. *Lancet (London,*
52
53
54
55
56
57
58
59
60

- 1
2
3 *England*) 2010;375(9731):2073-81. doi: 10.1016/s0140-6736(10)60674-5
4
5 [published Online First: 2010/05/21]
6
7
- 8 28. Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease
9
10 measures with mortality and end-stage renal disease in individuals with and
11
12 without hypertension: a meta-analysis. *Lancet (London, England)*
13
14 2012;380(9854):1649-61. doi: 10.1016/s0140-6736(12)61272-0 [published
15
16 Online First: 2012/09/28]
17
18
- 19 29. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures
20
21 with mortality and end-stage renal disease in individuals with and without
22
23 diabetes: a meta-analysis. *Lancet (London, England)* 2012;380(9854):1662-73.
24
25 doi: 10.1016/s0140-6736(12)61350-6 [published Online First: 2012/09/28]
26
27
- 28 30. Stevens PE, Levin A. Evaluation and management of chronic kidney disease:
29
30 synopsis of the kidney disease: improving global outcomes 2012 clinical practice
31
32 guideline. *Annals of internal medicine* 2013;158(11):825-30. doi: 10.7326/0003-
33
34 4819-158-11-201306040-00007 [published Online First: 2013/06/05]
35
36
- 37 31. Foster MC, Rawlings AM, Marrett E, et al. Cardiovascular risk factor burden,
38
39 treatment, and control among adults with chronic kidney disease in the United
40
41 States. *American heart journal* 2013;166(1):150-6. doi: 10.1016/j.ahj.2013.03.016
42
43 [published Online First: 2013/07/03]
44
45
- 46 32. Charytan DM, Wallentin L, Lagerqvist B, et al. Early angiography in patients with
47
48 chronic kidney disease: a collaborative systematic review. *Clinical journal of the*
49
50 *American Society of Nephrology : CJASN* 2009;4(6):1032-43. doi:
51
52 10.2215/cjn.05551008 [published Online First: 2009/05/09]
53
54
55
56
57
58
59

- 1
2
3 33. Ix JH, Mercado N, Shlipak MG, et al. Association of chronic kidney disease with
4
5 clinical outcomes after coronary revascularization: the Arterial Revascularization
6
7 Therapies Study (ARTS). *American heart journal* 2005;149(3):512-9. doi:
8
9 10.1016/j.ahj.2004.10.010 [published Online First: 2005/05/03]
10
11
12 34. Kaneko H, Yajima J, Oikawa Y, et al. Role of arterial stiffness and impaired renal
13
14 function in the progression of new coronary lesions after percutaneous coronary
15
16 intervention. *Cardiovascular intervention and therapeutics* 2013;28(1):56-62. doi:
17
18 10.1007/s12928-012-0135-y [published Online First: 2012/09/27]
19
20
21 35. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and
22
23 Management: A Review. *Jama* 2019;322(13):1294-304. doi:
24
25 10.1001/jama.2019.14745 [published Online First: 2019/10/02]
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 1. Percentages of hospitalizations with coronary angiography and**
4 **percutaneous coronary intervention for individuals with coronary heart disease**
5
6
7
8
9

10
11 Note: The number of hospitalizations with or without CKD was 3,116 and 68,616 for
12 STEMI, respectively; 2,645 and 25,057 for NSTEMI, respectively; and 124,388 and
13 1,519,864 for NACS, respectively. For 18,315 hospitalizations with available CKD
14 staging, 15.8%, 24.6%, 16.8%, and 42.9% of individuals were in stages 1–2, 3, 4, and 5,
15
16
17
18
19
20 respectively.

21
22 Abbreviations: CKD, chronic kidney disease; NACS, non-acute coronary syndrome;
23
24 NSTEMI, non-ST-segment-elevation myocardial infarction; STEMI, ST-segment-
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
elevation myocardial infarction.

Table 1. Characteristics of hospitalized patients with non-communicable chronic diseases stratified by the presence of chronic kidney disease

	CHD		Stroke		Hypertension		Diabetes		COPD		Cancer		Total	
	CKD	Non-CKD	CKD	Non-CKD	CKD	Non-CKD	CKD	Non-CKD	CKD	Non-CKD	CKD	Non-CKD	CKD	Non-CKD
Number	132032	1665601	79 906	1529843	348075	3322665	222157	1321816	22998	429475	25585	3698423	871742	18647248
Percentage (%)	0.7	8.5	0.4	7.8	1.8	17.0	1.1	6.8	0.1	2.2	0.4	19.0	4.5	95.5
Main outcomes														
Costs (1000 yuan)	11 (7-20)	9 (6-20)	11 (7-19)	9 (6-16)	10 (6-17)	9 (6-16)	10 (7-16)	9 (6-16)	12 (8-22)	10 (6-16)	11 (7-29)	10 (6-20)	9 (6-17)	8 (4-14)
Length of stay (days) †	11 (8-17)	9 (6-13)	12 (8-17)	11 (7-15)	11 (7-16)	9 (6-14)	12 (8-16)	10 (7-14)	12 (8-19)	10 (7-15)	11 (7-19)	8 (4-14)	11 (6-16)	8 (5-13)
Mortality (%)	3.5	1.4	3.5	1.5	1.8	0.9	1.8	0.9	4.9	1.9	5.0	1.0	1.8	0.6
Demographic characteristics														
Age (years)	71.4±11.8	68.1±12.0	69.1±13.0	65.9±12.9	64.7±14.3	65.7±12.3	63.7±13.2	63.3±12.8	76.7±9.6	72.8±10.3	67.1±13.8	56.7±13.3	57.7±17.0	52.7±17.6
Male (%)	60.2	55.4	62.6	55.1	59.4	52.2	57.6	53.1	76.6	71.7	63.4	49.7	57.3	45.6
Occupation (%) †														
Professional	7.6	8.7	8.0	8.5	9.8	9.2	11.0	11.2	4.2	4.2	10.4	11.1	11.9	14.4
Worker	4.9	5.3	5.6	5.9	5.9	5.9	6.5	6.3	3.8	4.7	6.2	6.2	6.6	7.1
Farmer	11.8	18.1	15.7	23.0	15.6	19.1	14.7	15.8	15.2	23.2	7.6	24.7	21.3	21.5
Retired	40.9	32.4	36.6	27.7	30.6	28.7	31.0	28.3	42.3	31.3	25.3	14.5	20.7	13.8
Unemployed	7.0	6.3	7.1	7.4	8.6	7.3	8.7	7.4	7.5	7.8	8.6	9.7	9.4	10.1
Others	27.8	29.4	27.0	27.4	29.5	29.9	28.2	31.1	27.1	28.9	11.9	33.7	30.2	33.1
Health insurance (%)														
Basic medical insurance	66.0	59.0	62.7	54.0	59.6	57.0	62.3	59.9	63.1	54.3	61.2	43.0	49.9	42.9
NRCMC	12.5	18.7	15.8	22.6	16.9	19.4	15.8	16.7	15.5	24.4	9.8	26.7	23.2	22.5
Others	11.0	11.6	9.8	10.3	10.6	10.3	9.9	10.3	10.2	10.0	13.6	12.7	11.4	13.0
Uninsured	10.5	10.8	11.8	13.1	12.9	13.3	12.0	13.1	11.2	11.3	15.5	17.6	15.4	21.6
Admission and comorbidity information														
Admission (%) †														
Emergency	21.6	22.6	25.3	29.3	17.3	20.5	16.5	16.9	22.9	23.1	20.8	7.4	16.1	17.9
Routine	71.6	69.4	68.3	63.2	76.0	72.2	76.6	75.1	69.1	68.9	80.1	82.4	76.0	72.6
Others	6.8	7.9	6.5	7.6	6.7	7.4	6.9	8.0	8.0	8.0	9.2	10.2	7.9	9.5
ICU stay (%)	4.1	3.0	3.9	2.7	2.4	2.0	2.2	1.7	5.1	3.2	3.0	0.7	2.0	1.2
Hypertension (%)	69.6	55.3	71.1	56.6	--	--	62.7	52.6	54.8	33.6	32.3	12.2	39.9	17.8
CHD (%)	--	--	28.2	18.7	26.4	27.7	26.8	25.8	35.9	23.0	28.4	2.9	15.2	8.9
Stroke (%)	17.1	17.1	--	--	16.3	26.0	14.8	18.9	12.7	9.5	4.8	1.8	9.2	8.2
COPD (%)	6.2	5.9	3.7	2.7	3.6	4.3	2.6	3.1	--	--	2.2	1.1	2.6	2.3
Cancer (%)	5.7	6.5	4.9	4.4	7.5	13.5	5.0	13.4	7.9	9.6	11.1	--	9.2	19.8

136/bmjopen-2021-05888 on 13 January 2022. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

Diabetes (%)	45.0	20.5	41.2	16.3	40.0	20.9	--	--	24.6	9.6	33.7	4.8	25.5	7.1
Pneumonia (%)	6.1	4.1	5.8	3.6	4.3	3.6	4.3	3.4	8.3	8.5	5.7	2.0	3.7	2.3
Sepsis (%)	0.5	0.2	0.7	0.2	0.5	0.2	0.7	0.3	0.7	0.3	0.6	0.2	0.6	0.2

†The percentages of missing values for occupation, type of admission, and length of stay were 10.9%, 6.4%, and 16.6% for CHD; 10.5%, 7.1%, and 17.5% for stroke; 10.7%, 6.7%, and 16.2% for hypertension; 10.7%, 6.9%, and 16.6% for diabetes; 12.2%, 5.4%, and 18.0% for COPD; and 11.4%, 6.1%, and 15.2% for cancer.

Abbreviations: CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; NCDs, non-communicable chronic diseases; NRCMC, New Rural Cooperative Medical Care.

Table 2. Effects of chronic kidney disease on length of stay, costs, and in-hospital mortality for each non-communicable disease

Condition	Covariates in the model	Length of stay % change (95% CI)	Costs % change (95% CI)	In-hospital mortality relative risk (95% CI)
CHD	Model 1	24.58 (24.1, 25.06)	4.96 (4.34, 5.58)	1.15 (2.08, 2.22)
	Model 2	21.99 (21.49, 22.5)	-0.26 (-0.90, 0.37)	1.09 (2.02, 2.16)
	Model 3	21.60 (21.09, 22.10)	-1.08 (-1.71, -0.45)	1.02 (1.95, 2.09)
Stroke	Model 1	11.35 (10.80, 11.90)	16.65 (15.81, 17.49)	1.17 (2.08, 2.26)
	Model 2	8.26 (7.68, 8.85)	13.05 (12.19, 13.91)	1.01 (1.92, 2.10)
	Model 3	7.69 (7.11, 8.28)	11.15 (10.31, 11.99)	1.09 (1.82, 1.99)
Hypertension	Model 1	14.46 (14.17, 14.74)	-0.40 (-0.76, -0.04)	1.04 (1.89, 2.00)
	Model 2	16.24 (15.92, 16.55)	0.49 (0.10, 0.87)	1.07 (1.91, 2.03)
	Model 3	16.01 (15.70, 16.33)	-0.22 (-0.60, 0.16)	1.09 (1.85, 1.97)
Diabetes	Model 1	14.05 (13.70, 14.41)	-2.90 (-3.33, -2.47)	1.08 (1.82, 1.95)
	Model 2	16.55 (16.16, 16.94)	-0.14 (-0.60, 0.33)	1.02 (1.94, 2.10)
	Model 3	16.32 (15.93, 16.70)	-0.97 (-1.43, -0.51)	1.05 (1.88, 2.03)
COPD	Model 1	15.85 (14.84, 16.87)	31.41 (29.78, 33.06)	1.21 (2.08, 2.35)
	Model 2	11.14 (10.11, 12.18)	20.15 (18.65, 21.68)	1.09 (1.86, 2.13)
	Model 3	11.05 (10.02, 12.09)	19.46 (17.97, 20.97)	1.07 (1.84, 2.11)
Cancer	Model 1	21.38 (20.66, 22.11)	25.84 (24.96, 26.72)	1.30 (3.19, 3.41)
	Model 2	17.87 (17.11, 18.64)	19.63 (18.72, 20.54)	1.07 (2.65, 2.85)
	Model 3	17.50 (16.74, 18.26)	18.88 (17.98, 19.78)	1.05 (2.55, 2.75)

Note: Numbers in the table are percent-changes/relative risks of patient records with CKD compared with patient records without CKD for each non-communicable disease. Percent of change (% change) and relative risk with 95% confidence interval (CI) were calculated as $\exp(\beta)-1$ from the generalized regression model and $\exp(\beta)$ from the Poisson regression model, respectively.

Covariates in model 1 included age and sex.

Covariates in model 2 included age, sex, occupation, type of health insurance, type of admission, intensive care unit stay, presence of CHD, stroke, hypertension, diabetes, COPD, and cancer (except for the disease used to define the subgroup).

Covariates in model 3 included covariates in model 2, plus the presence of sepsis and pneumonia.

Abbreviations: CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.

Table 3. Effects of chronic kidney disease on length of stay, costs, and in-hospital mortality, compared with other major non-communicable diseases

Condition	Covariates in the model	Length of stay % change (95% CI)	Costs % change (95% CI)	In-hospital mortality relative risk (95% CI)
CKD	Model 1	22.34 (22.14, 22.55)	6.49 (6.25, 6.73)	2.31 (2.27, 2.35)
	Model 2	22.09 (21.87, 22.32)	6.82 (6.56, 7.08)	2.23 (2.19, 2.28)
CHD	Model 1	-5.19 (-5.31, -5.07)	27.72 (27.51, 27.94)	1.36 (1.34, 1.38)
	Model 2	-7.31 (-7.44, -7.18)	30.95 (30.71, 31.19)	1.31 (1.29, 1.33)
Stroke	Model 1	16.12 (15.97, 16.27)	9.29 (9.10, 9.48)	1.58 (1.56, 1.60)
	Model 2	17.34 (17.17, 17.51)	9.90 (9.69, 10.11)	1.70 (1.67, 1.73)
Hypertension	Model 1	5.49 (5.39, 5.59)	8.90 (8.77, 9.04)	1.93 (0.92, 0.94)
	Model 2	1.81 (1.69, 1.92)	4.85 (4.70, 5.01)	1.76 (0.75, 0.77)
Diabetes	Model 1	11.36 (11.22, 11.51)	5.05 (4.87, 5.23)	1.13 (1.11, 1.15)
	Model 2	8.96 (8.80, 9.12)	1.00 (0.81, 1.20)	1.99 (0.97, 1.01)
COPD	Model 1	3.89 (3.65, 4.14)	-9.00 (-9.29, -8.71)	1.31 (1.28, 1.34)
	Model 2	5.77 (5.50, 6.04)	-8.67 (-8.98, -8.36)	1.24 (1.21, 1.27)
Cancer	Model 1	8.90 (8.80, 9.00)	27.40 (27.25, 27.55)	2.00 (1.97, 2.02)
	Model 2	13.90 (13.79, 14.02)	39.47 (39.29, 39.65)	2.87 (2.83, 2.91)

1
2
3
4
5 Note: Numbers in the table are percent-changes/relative risks of patient records with corresponding disease compared with patient
6 records without corresponding disease. Percent of change (% change) and relative risk with 95% confidence interval (CI) were
7 calculated as $\exp(\beta)-1$ from the generalized regression model and $\exp(\beta)$ from the Poisson regression model, respectively.
8
9

10
11 Covariates in model 1 included age and sex.

12
13 Covariates in model 2 included age, sex, occupation, type of health insurance, type of admission, intensive care unit stay, presence of
14 CKD, CHD, stroke, hypertension, diabetes, COPD, and cancer, and presence of sepsis and pneumonia.
15
16

17 Abbreviations: CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
pulmonary disease.




Figure 1. Percentages of coronary angiography and percutaneous coronary intervention for hospitalizations with coronary heart disease

Note: The number of hospitalizations with or without CKD was 3,116 and 68,616 for STEMI, 2,645 and 25,057 for NSTEMI, 124,388 and 1,519,864 for NACS, respectively. For 18,315 hospitalizations with diagnoses of CKD staging, 15.8%, 24.6%, 16.8%, and 42.9% of them were in stage 1-2, 3, 4 and 5.

Abbreviations: CKD, chronic kidney disease; NACS, non-acute coronary syndrome; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.

227x170mm (600 x 600 DPI)

136/bmjopen-2021-051888 on 13 January 2022. Downloaded from <http://bmjopen.bmj.com/>. Protected by copyright.

Appendix 1. The International Classification of Diseases-10 coding of chronic kidney disease and other major non-communicable chronic diseases

Disease	ICD-10 coding
CKD	E10.2+, E11.2+, E13.2+, E14.2+, I12.0, I12.9, I13.0, I13.1, I13.2, I13.9, N11, N12, N14, N15, N16.* , E74.8, E72.0, N25.1, M32.1+N08.5* , M32.1+N16.4* , M35.0+N16.4* , M31.0+N08.5* , M31.7+N08.5* , M31.001 [†] , M31.802 [†] , M31.011+N08.5* [†] , M31.102+N08.5* [†] , M31.303+N08.5* [†] , N18, N19, N13.0, N13.1, N13.2, C64, N07, N08 (excluding N08.5*), N13.6, Q60, Q61.1, Q61.2, Q61.3, Q61.5, Q63.1, Q63.9, M10.3, N26, N28.0, N28.8, N28.9, A52.7+N08.0* , N99.0, P96.0, R39.2, K76.7, Q27.1, I70.1, M31.4 (combined with I15.0) N00.8, N02, N03, N04, N05, N06, N39.1
CHD [†]	I21.001, I21.002, I21.004, I21.101, I21.103, I21.104, I21.105, I21.201, I21.202, I21.203, I21.204, I21.205, I21.206, I21.207, I21.208, I21.209, I21.210, I21.211, I21.213, I21.214, I21.215, I21.301, I21.302, I21.304, I21.907, I21.403, I24.003, I20.001, I20.002, I20.003, I20.004, I20.005, I20.006, I20.101, I20.102, I20.802, I20.803, I21.303, I21.401, I21.402, I21.901, I21.902, I21.910, I22.001, I22.101, I22.801, I22.802, I22.803, I22.901, I23.001, I23.002, I23.101, I23.201, I23.301, I24.001, I24.002, I24.003, I24.004, I24.005, I24.006, I24.101, I24.102, I24.801, I24.802, I24.901, I20.801, I20.804, I20.805, I20.806, I20.902, I25.103, I25.104, I25.105, I25.201, I25.202, I25.203, I25.204, I25.205, I25.206, I25.207, I25.208, I25.209, I25.210, I25.211, I25.212, I25.213, I25.214, I25.215, I25.501, I25.601, I25.901, I25.902
CHD [†]	I21.000, I21.001, I21.002, I21.003, I21.004, I21.005, I21.006, I21.007, I21.100, I21.101, I21.102, I21.103, I21.104, I21.105, I21.200, I21.201, I21.202, I21.203, I21.204, I21.205, I21.206, I21.300, I21.301, I21.401, I20.000, I20.001, I20.002, I20.003, I20.004, I20.005, I20.006, I20.100, I20.101, I20.102, I20.804, I21.302, I21.303, I21.400, I21.402, I21.900, I22.000, I22.000, I22.800, I22.900, I23.000, I23.100, I23.200, I23.300, I23.400, I23.500, I23.600, I23.601, I23.800, I24.000, I24.001, I24.100, I24.001, I24.800, I24.801, I24.900, I24.901, I20.801, I20.802, I20.803, I20.804, I20.900, I25.000, I25.100, I25.101, I25.102, I25.103, I25.100, I25.500, I25.600, I25.800, I25.801, I25.900, I25.901,
COPD	J44.901 [†] , J44.003 [†] , J44.103 [†] , J44.900 [†] , J44.000 [†] , J44.100 [†] , J44.800 [†]
Stroke	I60, I61, I63, I64, G45, H34.1
Diabetes	E10, E11, E12, E13, E14
Cancer	C00-C26, C30-C34, C37-C41, C43-C58, C60-C85, C88, C90-C97, D00-D07, D09, D37-D48, B21, Z85, Z88, Z51.10 [†] , Z51.20 [†] , Z51.50 [†] , Z03.101 [†] , E87.805 [†] , O99.8011 [†] , O99.8021 [†] , O99.8024 [†] , O99.8031 [†] , Z51.00 [†] , Z51.10 [†] , Z51.80 [†] , Z03.10 [†] , O99.802 [†] , Z35.802 [†] , Z54.001 [†] , E88.805 [†] , Z86.000 [†]
Hypertension	I10

Disease	ICD-10 coding
Sepsis	A41
Pneumonia	J12-J18

¹Applicable for ICD-10 (Beijing Version 4.0) only.

[‡]Applicable for ICD-10 (National Standard Version1.0) only.

^{*}Denotes to any possible number so that the whole sequence represents all the subclasses of the disease.

Abbreviations: CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary diseases. ICD-10, International Classification of Diseases-10.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Appendix 2. Effects of chronic kidney disease stages 3-5 on length of stay, costs, and in-hospital mortality for each non-communicable disease

Condition	Covariates in the model	Length of stay % change (95% CI)	Costs % change (95% CI)	In-hospital mortality relative risk (95% CI)
CHD	Model 1	36.67 (35.19, 38.17)	14.54 (12.64, 16.47)	1.90 (1.73, 2.08)
	Model 2	38.68 (37.07, 40.30)	6.22 (4.35, 8.13)	1.93 (1.76, 2.13)
	Model 3	38.41 (36.81, 40.03)	5.69 (3.83, 7.58)	1.93 (1.76, 2.13)
Stroke	Model 1	22.81 (20.89, 24.75)	30.39 (27.46, 33.38)	1.12 (1.88, 2.39)
	Model 2	21.76 (19.67, 23.88)	25.48 (22.49, 28.55)	1.92 (1.69, 2.19)
	Model 3	21.13 (19.05, 23.24)	23.60 (20.66, 26.60)	1.79 (1.58, 2.05)
Hypertension	Model 1	19.77 (19.01, 20.54)	0.62 (-0.29, 1.53)	1.60 (1.49, 1.72)
	Model 2	25.88 (25.02, 26.75)	4.10 (3.10, 5.11)	1.83 (1.69, 1.98)
	Model 3	25.69 (24.83, 26.55)	3.47 (2.48, 4.47)	1.76 (1.63, 1.91)
Diabetes	Model 1	23.75 (22.71, 24.80)	10.24 (8.92, 11.58)	1.91 (1.75, 2.09)
	Model 2	29.22 (28.06, 30.40)	13.22 (11.80, 14.65)	2.14 (1.95, 2.36)
	Model 3	29.06 (27.90, 30.23)	12.55 (11.15, 13.98)	2.13 (1.93, 2.34)
COPD	Model 1	14.97 (11.79, 18.25)	36.41 (31.07, 41.97)	1.70 (1.37, 2.12)
	Model 2	15.21 (11.75, 18.77)	22.93 (17.93, 28.14)	1.74 (1.38, 2.19)
	Model 3	15.38 (11.92, 18.95)	22.80 (17.83, 27.97)	1.72 (1.36, 2.16)
Cancer	Model 1	24.54 (21.36, 27.80)	20.65 (17.08, 24.34)	1.15 (1.86, 2.49)
	Model 2	20.58 (17.23, 24.02)	12.13 (8.53, 15.85)	1.68 (1.44, 1.95)
	Model 3	19.72 (16.40, 23.14)	11.26 (7.70, 14.94)	1.49 (1.28, 1.73)

Note: Numbers in the table are percent-changes/relative risks of patient records with CKD compared with patient records without CKD

1
2
3
4
5 for each non-communicable disease. Percent of change (% change) and relative risk with 95% confidence interval (CI) were calculated
6
7 as $\exp(\beta)-1$ from the generalized regression model and $\exp(\beta)$ from the Poisson regression model, respectively.

8
9 Covariates in model 1 included age and sex.

10
11 Covariates in model 2 included age, sex, occupation, type of health insurance, type of admission, intensive care unit stay, presence of
12
13 CHD, stroke, hypertension, diabetes, COPD, and cancer (except for the disease used to define the subgroup).

14
15
16 Covariates in model 3 included covariates in model 2, plus the presence of sepsis and pneumonia.

17
18 Abbreviations: CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
pulmonary disease.

Appendix 3. Effects of chronic kidney disease stages 3-5 on length of stay, costs, and in-hospital mortality, compared with other major non-communicable diseases

Condition	Covariates in the model	Length of stay % change (95% CI)	Costs % change (95% CI)	In-hospital mortality relative risk (95% CI)
CKD	Model 1	32.02 (31.40, 32.65)	14.97 (14.26, 15.70)	1.76 (1.67, 1.85)
	Model 2	35.61 (34.93, 36.30)	19.65 (18.86, 20.45)	1.92 (1.82, 2.02)
CHD	Model 1	-5.95 (-6.08, -5.83)	28.00 (27.78, 28.22)	1.34 (1.32, 1.36)
	Model 2	-7.67 (-7.80, -7.53)	31.31 (31.06, 31.56)	1.32 (1.29, 1.34)
Stroke	Model 1	16.71 (16.55, 16.86)	9.00 (8.81, 9.20)	1.62 (1.60, 1.65)
	Model 2	17.76 (17.59, 17.94)	9.58 (9.37, 9.80)	1.74 (1.71, 1.77)
Hypertension	Model 1	5.07 (4.97, 5.18)	9.26 (9.11, 9.40)	0.92 (0.91, 0.93)
	Model 2	2.15 (2.03, 2.26)	5.11 (4.95, 5.27)	0.78 (0.76, 0.79)
Diabetes	Model 1	10.38 (10.23, 10.53)	5.90 (5.70, 6.10)	1.09 (1.07, 1.11)
	Model 2	9.54 (9.37, 9.71)	1.90 (1.69, 2.11)	1.03 (1.01, 1.05)
COPD	Model 1	3.99 (3.74, 4.24)	-9.96 (-10.25, -9.67)	1.32 (1.29, 1.35)
	Model 2	5.83 (5.56, 6.11)	-9.48 (-9.80, -9.17)	1.24 (1.21, 1.27)
Cancer	Model 1	9.51 (9.41, 9.60)	26.96 (26.80, 27.11)	2.00 (1.98, 2.03)
	Model 2	14.07 (13.95, 14.18)	38.95 (38.76, 39.13)	2.87 (2.82, 2.91)

Note: Numbers in the table are percent-changes/relative risks of patient records with corresponding disease compared with patient records without

1
2
3
4
5 corresponding disease. Percent of change (% change) and relative risk with 95% confidence interval (CI) were calculated as $\exp(\beta)-1$ from the
6
7
8 generalized regression model and $\exp(\beta)$ from the Poisson regression model, respectively.
9

10
11 Covariates in model 1 included age and sex.

12
13 Covariates in model 2 included age, sex, occupation, type of health insurance, type of admission, intensive care unit stay, presence of CKD, CHD,
14
15 stroke, hypertension, diabetes, COPD, and cancer, and presence of sepsis and pneumonia.
16
17

18
19 Abbreviations: CHD, coronary heart disease; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6-7
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-10
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	-
		(d) If applicable, describe analytical methods taking account of sampling strategy	10
		(e) Describe any sensitivity analyses	-
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11
		(b) Indicate number of participants with missing data for each variable of interest	-
Outcome data	15*	Report numbers of outcome events or summary measures	11-13

